Morquio syndrome

Mendelian MONDO:0018938 Pathograph 27 Mucopolysaccharidosis Lysosomal Storage Disorder

Morquio syndrome, or mucopolysaccharidosis type IV (MPS IV), is a lysosomal storage skeletal dysplasia caused by defective lysosomal degradation of keratan sulfate. Type A results from GALNS deficiency and causes storage of both keratan sulfate and chondroitin-6-sulfate, whereas Type B results from GLB1 deficiency with keratan-sulfate-dominant beta-galactosidase dysfunction. Storage in cartilage and other connective tissues disrupts chondrocyte biology, extracellular matrix organization, endochondral ossification, and ligament stability, producing short-trunk short stature, dysostosis multiplex, joint laxity, odontoid hypoplasia, cervical cord compression, airway obstruction, corneal clouding, hearing loss, and valve disease. Intelligence is usually preserved. Elosulfase alfa is disease-modifying for Type A, while both subtypes require intensive orthopedic, airway, and supportive management.

Ask OpenScientist

Ask a research question about Morquio syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Inheritance
10
Pathophys.
11
Phenotypes
27
Pathograph
2
Genes
4
Treatments
2
Subtypes
13
References
1
Deep Research
🔗

Mappings

MONDO
MONDO:0018938 mucopolysaccharidosis type 4
skos:exactMatch MONDO
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
Both Morquio subtypes are autosomal recessive lysosomal storage disorders.
Autosomal recessive inheritance
Show evidence (2 references)
PMID:33256811 SUPPORT Human Clinical
"Mucopolysaccharidosis (MPS) IVA, also known as Morquio A syndrome, is a rare autosomal recessive lysosomal storage disorder caused by a deficiency in the enzyme N-acetylgalactosamine-6-sulfatase."
This directly supports autosomal recessive inheritance for Type A.
PMID:21497194 SUPPORT Human Clinical
"GM1 gangliosidosis and Morquio B are autosomal recessive storage disorders caused by the deficiency of β-galactosidase (GLB1), a lysosomal hydrolase that may be defective with respect to keratan sulfate (in Morquio B disease)"
This directly supports autosomal recessive inheritance for Type B.
◆

Subtypes

2
Type A (MPS IVA, GALNS) MONDO:0009659
GALNS-related Morquio syndrome with deficiency of N-acetylgalactosamine-6-sulfatase. Type A stores both keratan sulfate and chondroitin-6-sulfate and is the Morquio subtype for which elosulfase alfa enzyme replacement therapy is approved.
Show evidence (2 references)
PMID:32905071 SUPPORT Human Clinical
"Mucopolysaccharidosis type IVA (MPS IVA) is an inborn error of glycosaminoglycan (GAG) catabolism characterized by a deficiency of the lysosomal enzyme, N-acetylgalactosamine 6-sulphatase (GALNS)."
This directly defines Type A as the GALNS-deficient Morquio subtype.
CGGV:assertion_c58d08e9-dc6d-45fc-a21a-54be3bc438d9-2022-06-16T040000.000Z SUPPORT Other
"GALNS | HGNC:4122 | mucopolysaccharidosis type 4A | MONDO:0009659 | AR | Definitive"
ClinGen's Lysosomal Diseases GCEP classifies the GALNS-MPS IVA gene-disease relationship as Definitive with autosomal recessive inheritance.
Type B (MPS IVB, GLB1) MONDO:0009660
GLB1-related Morquio syndrome with beta-galactosidase deficiency and keratan-sulfate-dominant storage. Type B is usually attenuated relative to Type A, although intermediate GLB1 phenotypes bridging GM1 gangliosidosis and Morquio B have been reported.
Show evidence (2 references)
PMID:33558080 SUPPORT Human Clinical
"Morquio B disease is an attenuated phenotype within the spectrum of beta galactosidase (GLB1) deficiencies."
This directly defines Type B as a GLB1-related Morquio phenotype and supports retaining it as an explicit subtype.
CGGV:assertion_9e170fda-e08a-4fd3-a3e5-f08c5c0d55b8-2023-04-28T160000.000Z SUPPORT Other
"GLB1 | HGNC:4298 | mucopolysaccharidosis type 4B | MONDO:0009660 | AR | Definitive"
ClinGen's Lysosomal Diseases GCEP classifies the GLB1-MPS IVB gene-disease relationship as Definitive with autosomal recessive inheritance.
⚙

Pathophysiology

10
Type A GALNS deficiency
In Morquio type A, GALNS deficiency blocks lysosomal degradation of keratan sulfate and chondroitin-6-sulfate.
GALNS link
glycosaminoglycan catabolic process link ↓ DECREASED
Downstream
Keratan sulfate-dominant lysosomal storage in cartilage and connective tissue Loss of GALNS activity causes lysosomal storage of keratan sulfate and chondroitin-6-sulfate in connective tissues.
Show evidence (1 reference)
PMID:32905071 SUPPORT Human Clinical
"Mucopolysaccharidosis type IVA (MPS IVA) is an inborn error of glycosaminoglycan (GAG) catabolism characterized by a deficiency of the lysosomal enzyme, N-acetylgalactosamine 6-sulphatase (GALNS)."
This directly supports GALNS deficiency as the proximal defect in Type A disease.
Type B GLB1 deficiency with keratan sulfate-biased catalytic loss
In Morquio type B, GLB1 mutations create a beta-galactosidase deficiency phenotype in which keratan sulfate handling is disproportionately impaired, producing a skeletal/connective-tissue presentation rather than classic GM1 gangliosidosis.
GLB1 link
beta-galactosidase activity link ↓ DECREASED
Downstream
Keratan sulfate-dominant lysosomal storage in cartilage and connective tissue GLB1 substrate imbalance produces keratan-sulfate-dominant storage in connective tissues.
Show evidence (2 references)
PMID:21497194 SUPPORT Human Clinical
"GM1 gangliosidosis and Morquio B syndrome, both arising from beta-galactosidase (GLB1) deficiency, are very rare lysosomal storage diseases"
This directly identifies GLB1 deficiency as the proximal lesion in Morquio B disease.
PMID:12559848 SUPPORT In Vitro
"These findings suggest that imbalanced substrate specificity of the mutant beta-Gals induces predominant accumulation of keratan sulfate and a rationale for performing differential diagnostic analysis for both disorders."
Fibroblast kinetic studies show why GLB1-related Morquio disease is keratan-sulfate dominant rather than a generic beta-galactosidase phenotype.
Keratan sulfate-dominant lysosomal storage in cartilage and connective tissue
Keratan sulfate accumulates in both Morquio subtypes; Type A also stores chondroitin-6-sulfate. Storage is concentrated in cartilage and other connective tissues, where distended lysosomes initiate downstream tissue injury.
chondrocyte link fibroblast link
lysosome link
cartilage tissue link
Downstream
Cartilage matrix dysfunction and impaired endochondral ossification Storage distends chondrocytes and disrupts cartilage extracellular matrix and growth plate biology.
Corneal and valvular connective tissue involvement Storage extends beyond the skeleton to cornea and cardiac valves.
Show evidence (2 references)
PMID:32905071 SUPPORT Human Clinical
"Consequently, partially degraded GAG, chondroitin 6-sulfate (CS) and keratan sulfate (KS), accumulate in the lysosomes of affected cells, primarily in cartilage resulting in skeletal disease."
This directly supports the Type A storage node and cartilage-predominant tissue distribution.
PMID:12559848 SUPPORT In Vitro
"These findings suggest that imbalanced substrate specificity of the mutant beta-Gals induces predominant accumulation of keratan sulfate and a rationale for performing differential diagnostic analysis for both disorders."
This provides subtype B support for the same keratan-sulfate-dominant storage node.
Cartilage matrix dysfunction and impaired endochondral ossification
Glycosaminoglycan storage in cartilage, ligaments, and their extracellular matrix balloons chondrocytes and impedes endochondral ossification and chondrogenesis.
growth plate cartilage chondrocyte link
endochondral ossification link ↓ DECREASED cartilage development link ↓ DECREASED extracellular matrix organization link
growth plate cartilage link skeletal ligament link
Downstream
Progressive skeletal dysplasia and joint laxity Defective cartilage and growth plate biology generates dysostosis multiplex, short stature, limb deformity, and joint laxity.
Show evidence (2 references)
PMID:29326877 SUPPORT Human Clinical
"As a result, partially degraded GAGs accumulate in bone, ligaments, and cartilage, as well as the extracellular matrix (ECM) of these tissues, impeding endochondral ossification and chondrogenesis"
This directly supplies the mechanistic bridge from storage to cartilage/connective-tissue dysfunction.
PMID:29326877 SUPPORT Human Clinical
"Examination of the tissues demonstrated systemic storage materials in multiple tissues, as well as severely ballooned and vacuolated chondrocytes in the trachea, humerus, knee cartilage, and lung bronchus."
Human autopsy pathology confirms distorted chondrocyte morphology in multiple disease-relevant tissues.
Progressive skeletal dysplasia and joint laxity
Morquio syndrome expresses its core phenotype as progressive dysostosis multiplex, short stature, kyphoscoliosis, limb deformity, and joint laxity.
Downstream
Craniovertebral instability Odontoid hypoplasia and ligamentous laxity destabilize the craniovertebral junction.
Structural airway narrowing Skeletal chest/airway distortion and tracheal connective-tissue disease produce fixed airway narrowing.
Dysostosis multiplex The progressive skeletal branch manifests clinically as dysostosis multiplex.
Short stature Impaired growth plate and skeletal development produce disproportionate short stature.
Pectus carinatum Thoracic skeletal dysplasia produces pectus carinatum.
Genu valgum Lower-extremity skeletal dysplasia produces genu valgum.
Joint laxity Ligament and joint connective-tissue disease manifests as joint laxity.
Hypoplasia of the odontoid process Morquio skeletal dysplasia includes odontoid hypoplasia, which sets up craniovertebral instability.
Show evidence (2 references)
PMID:29326877 SUPPORT Human Clinical
"The accumulation of these GAGs leads to distinguishing features as skeletal dysplasia with disproportionate dwarfism, short neck, kyphoscoliosis, pectus carinatum, tracheal obstruction, coxa valga, genu valgum, and joint laxity."
This directly supports the shared skeletal/connective-tissue phenotype cluster downstream of storage.
PMID:32071837 SUPPORT Human Clinical
"Forty-one of 51 cases with informative clinical data had pure MBD including progressive growth impairment, kyphoscoliosis, coxa/genua valga, joint laxity, platyspondyly, odontoid hypoplasia."
This extends the same skeletal/joint phenotype cluster explicitly into Morquio B disease.
Craniovertebral instability
Odontoid hypoplasia, atlantoaxial instability, and cervical canal narrowing destabilize the craniovertebral junction.
atlanto-axial joint link
Downstream
Cervical spinal cord compression Craniovertebral instability and canal compromise threaten the cervical cord and can produce myelopathy.
Show evidence (1 reference)
PMID:29326877 SUPPORT Human Clinical
"Individuals with MPS IVA, particularly with the severe form, often do not survive past their twenties, as the most attributed causes of mortality and morbidity are spinal cord compression, instability of the C1-C2 joint, and airway compromise including tracheal obstruction"
This directly supports instability of the C1-C2 joint as a terminal high-risk Morquio mechanism.
Cervical spinal cord compression
Craniovertebral instability and cervical canal compromise can compress the cervical spinal cord and produce myelopathy.
Downstream
Spinal cord compression Cervical cord compression is the mechanism-level correlate of the spinal cord compression phenotype.
Show evidence (2 references)
PMID:29326877 SUPPORT Human Clinical
"Individuals with MPS IVA, particularly with the severe form, often do not survive past their twenties, as the most attributed causes of mortality and morbidity are spinal cord compression, instability of the C1-C2 joint, and airway compromise including tracheal obstruction"
This directly supports cervical spinal cord compression as a terminal high-risk Morquio mechanism.
PMID:32071837 PARTIAL Human Clinical
"Corneal clouding, cardiac valve pathology, hepatosplenomegaly, spinal cord compression were infrequent"
This shows that spinal cord compression can occur in Type B, but should be framed as infrequent rather than core.
Structural airway narrowing
Glycosaminoglycan-loaded tracheal cartilage together with thoracic and cervicothoracic skeletal distortion produces fixed upper-airway and tracheal narrowing.
trachea link
Downstream
Respiratory compromise Progressive fixed airway narrowing impairs ventilation and drives respiratory distress.
Upper airway obstruction Fixed airway narrowing is clinically captured as upper-airway/tracheal obstruction.
Show evidence (2 references)
PMID:29326877 SUPPORT Human Clinical
"This autopsied case with MPS IVA addresses the importance of tracheal obstruction for morbidity and mortality of the disease"
This directly supports structural airway obstruction as a major Morquio mechanism.
DOI:10.1186/s13023-024-03253-3 SUPPORT Human Clinical
"These manifestations of end-stage disease are engendered by an insidious progression of multi-level airway pathologies, comprising of tracheomalacia, stenosis, tortuosity and 'buckling'."
This recent case series directly supports the structural, multi-level airway-narrowing mechanism in severe Morquio A.
Respiratory compromise
Progressive upper-airway and tracheal narrowing reduce ventilation and can lead to respiratory distress, chronic respiratory disease, and mortality.
Show evidence (2 references)
PMID:29326877 SUPPORT Human Clinical
"Individuals with MPS IVA, particularly with the severe form, often do not survive past their twenties, as the most attributed causes of mortality and morbidity are spinal cord compression, instability of the C1-C2 joint, and airway compromise including tracheal obstruction"
This directly supports respiratory compromise as a downstream consequence of Morquio airway disease.
PMID:25346323 SUPPORT Other
"Morquio A syndrome (mucopolysaccharidosis IVA) is a lysosomal storage disorder associated with skeletal and joint abnormalities and significant non-skeletal manifestations including respiratory disease, spinal cord compression, cardiac disease, impaired vision, hearing loss, and dental problems."
International guidelines confirm that respiratory disease is a central Morquio manifestation and should remain explicit in the pathograph.
Corneal and valvular connective tissue involvement
Storage outside cartilage affects cornea and cardiac valves, contributing to corneal clouding, impaired vision, hearing loss, and valve disease.
cornea link cardiac valve link
Downstream
Corneal opacity Corneal connective-tissue involvement manifests as corneal clouding/opacity.
Hearing abnormality Extra-skeletal craniofacial and ENT involvement contributes to hearing loss.
Abnormal heart valve morphology Valvular connective-tissue involvement manifests as abnormal cardiac valve morphology.
Show evidence (2 references)
PMID:25346323 SUPPORT Other
"Morquio A syndrome (mucopolysaccharidosis IVA) is a lysosomal storage disorder associated with skeletal and joint abnormalities and significant non-skeletal manifestations including respiratory disease, spinal cord compression, cardiac disease, impaired vision, hearing loss, and dental problems."
This supports a non-skeletal connective-tissue branch involving vision, hearing, and cardiac disease.
PMID:33558080 SUPPORT Human Clinical
"It is characterised by dysostosis multiplex, ligament laxity, mildly coarse facies and heart valve defects due to keratan sulphate accumulation, predominantly in the cartilage."
This extends the same connective-tissue branch into Morquio B with explicit heart valve involvement.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Morquio syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

11
Cardiovascular 1
Abnormal heart valve morphology Abnormal heart valve morphology (HP:0001654)
Show evidence (2 references)
PMID:25346323 SUPPORT Other
"Morquio A syndrome (mucopolysaccharidosis IVA) is a lysosomal storage disorder associated with skeletal and joint abnormalities and significant non-skeletal manifestations including respiratory disease, spinal cord compression, cardiac disease, impaired vision, hearing loss, and dental problems."
Guidelines explicitly include cardiac disease among the major Morquio A manifestations.
PMID:33558080 SUPPORT Human Clinical
"It is characterised by dysostosis multiplex, ligament laxity, mildly coarse facies and heart valve defects due to keratan sulphate accumulation, predominantly in the cartilage."
This directly supports heart valve disease in Morquio B.
Eye 1
Corneal opacity Corneal opacity (HP:0007957)
Show evidence (2 references)
PMID:29054894 SUPPORT Human Clinical
"MPS type IVA (Morquio A syndrome) has predominant musculoskeletal system involvement and corneal clouding with normal intelligence and can be misdiagnosed as primary skeletal disorders in clinical practice."
This directly supports corneal clouding as a core Type A feature.
PMID:8233358 SUPPORT Human Clinical
"In addition to the characteristic dwarfism with skeletal deformities, odontoid anomalies, hearing loss and corneal clouding, the authors found almost identical lens opacities in all three patients."
This independently confirms corneal clouding in Type A disease.
Limbs 1
Genu valgum Genu valgum (HP:0002857)
Show evidence (1 reference)
PMID:29326877 SUPPORT Human Clinical
"The accumulation of these GAGs leads to distinguishing features as skeletal dysplasia with disproportionate dwarfism, short neck, kyphoscoliosis, pectus carinatum, tracheal obstruction, coxa valga, genu valgum, and joint laxity."
This directly lists genu valgum as a distinguishing skeletal manifestation.
Musculoskeletal 4
Dysostosis multiplex Dysostosis multiplex (HP:0000943)
Show evidence (1 reference)
PMID:33558080 SUPPORT Human Clinical
"It is characterised by dysostosis multiplex, ligament laxity, mildly coarse facies and heart valve defects due to keratan sulphate accumulation, predominantly in the cartilage."
This directly identifies dysostosis multiplex as a defining Morquio phenotype.
Pectus carinatum Pectus carinatum (HP:0000768)
Show evidence (1 reference)
PMID:29326877 SUPPORT Human Clinical
"The accumulation of these GAGs leads to distinguishing features as skeletal dysplasia with disproportionate dwarfism, short neck, kyphoscoliosis, pectus carinatum, tracheal obstruction, coxa valga, genu valgum, and joint laxity."
This directly lists pectus carinatum among the distinguishing Morquio skeletal features.
Joint laxity Joint hypermobility (HP:0001382)
Show evidence (2 references)
PMID:29326877 SUPPORT Human Clinical
"The accumulation of these GAGs leads to distinguishing features as skeletal dysplasia with disproportionate dwarfism, short neck, kyphoscoliosis, pectus carinatum, tracheal obstruction, coxa valga, genu valgum, and joint laxity."
This directly lists joint laxity as a distinguishing Morquio manifestation.
PMID:32071837 SUPPORT Human Clinical
"Forty-one of 51 cases with informative clinical data had pure MBD including progressive growth impairment, kyphoscoliosis, coxa/genua valga, joint laxity, platyspondyly, odontoid hypoplasia."
This confirms joint laxity also belongs to the Morquio B phenotype.
Hypoplasia of the odontoid process Hypoplasia of the odontoid process (HP:0003311)
Show evidence (2 references)
PMID:32071837 SUPPORT Human Clinical
"Forty-one of 51 cases with informative clinical data had pure MBD including progressive growth impairment, kyphoscoliosis, coxa/genua valga, joint laxity, platyspondyly, odontoid hypoplasia."
This directly supports odontoid hypoplasia as a Morquio skeletal phenotype.
PMID:8233358 SUPPORT Human Clinical
"In addition to the characteristic dwarfism with skeletal deformities, odontoid anomalies, hearing loss and corneal clouding, the authors found almost identical lens opacities in all three patients."
This confirms odontoid anomalies in Type A disease as well.
Respiratory 1
Upper airway obstruction Upper airway obstruction (HP:0002781)
Show evidence (1 reference)
PMID:29326877 SUPPORT Human Clinical
"This autopsied case with MPS IVA addresses the importance of tracheal obstruction for morbidity and mortality of the disease"
This directly supports life-limiting airway obstruction in severe Morquio A syndrome.
Growth 1
Short stature Short stature (HP:0004322)
Show evidence (1 reference)
PMID:29326877 SUPPORT Human Clinical
"The accumulation of these GAGs leads to distinguishing features as skeletal dysplasia with disproportionate dwarfism, short neck, kyphoscoliosis, pectus carinatum, tracheal obstruction, coxa valga, genu valgum, and joint laxity."
Disproportionate dwarfism directly supports short stature as a core Morquio phenotype.
Other 2
Spinal cord compression Spinal cord compression (HP:0002176)
Show evidence (1 reference)
PMID:29326877 SUPPORT Human Clinical
"Individuals with MPS IVA, particularly with the severe form, often do not survive past their twenties, as the most attributed causes of mortality and morbidity are spinal cord compression, instability of the C1-C2 joint, and airway compromise including tracheal obstruction"
This directly supports spinal cord compression as a severe Type A complication.
Hearing abnormality Hearing abnormality (HP:0000364)
Show evidence (2 references)
PMID:25346323 SUPPORT Other
"Morquio A syndrome (mucopolysaccharidosis IVA) is a lysosomal storage disorder associated with skeletal and joint abnormalities and significant non-skeletal manifestations including respiratory disease, spinal cord compression, cardiac disease, impaired vision, hearing loss, and dental problems."
Guidelines explicitly include hearing loss among the significant non-skeletal manifestations of Morquio A.
PMID:8233358 SUPPORT Human Clinical
"In addition to the characteristic dwarfism with skeletal deformities, odontoid anomalies, hearing loss and corneal clouding, the authors found almost identical lens opacities in all three patients."
This provides direct patient-level support for hearing loss in Morquio syndrome.
🧬

Genetic Associations

2
GALNS (Causative)
Show evidence (1 reference)
PMID:32905071 SUPPORT Human Clinical
"Mucopolysaccharidosis type IVA (MPS IVA) is an inborn error of glycosaminoglycan (GAG) catabolism characterized by a deficiency of the lysosomal enzyme, N-acetylgalactosamine 6-sulphatase (GALNS)."
This directly identifies GALNS as the causative gene/enzyme in Type A disease.
GLB1 (Causative)
Show evidence (2 references)
PMID:21497194 SUPPORT Human Clinical
"GM1 gangliosidosis and Morquio B syndrome, both arising from beta-galactosidase (GLB1) deficiency, are very rare lysosomal storage diseases"
This directly supports GLB1 as the causative gene for Morquio B disease.
PMID:33558080 SUPPORT Human Clinical
"Morquio B disease is an attenuated phenotype within the spectrum of beta galactosidase (GLB1) deficiencies."
This supports retaining GLB1-related Morquio disease as an explicit Type B subtype.
💊

Treatments

4
Type A elosulfase alfa enzyme replacement therapy
Action: enzyme replacement therapy Ontology label: enzyme replacement or supplementation therapy MAXO:0000933
Weekly intravenous recombinant GALNS replaces the deficient Type A enzyme, lowers storage biomarkers, and improves endurance, respiratory function, and growth-related outcomes. Skeletal, tracheal, and ocular tissues remain only partially responsive because of limited penetration.
Mechanism Target:
RESTORES Type A GALNS deficiency — Recombinant GALNS replaces the missing lysosomal enzyme in Type A disease.
Show evidence (1 reference)
PMID:26331768 SUPPORT Human Clinical
"Early intervention with elosulfase alfa is well-tolerated and produces a decrease in uKS and a trend toward improvement in growth."
Lower uKS with clinical improvement supports restoration of proximal Type A enzymatic function.
INHIBITS Keratan sulfate-dominant lysosomal storage in cartilage and connective tissue — Lower urinary keratan sulfate indicates partial suppression of the systemic storage burden.
Show evidence (1 reference)
PMID:26331768 SUPPORT Human Clinical
"Early intervention with elosulfase alfa is well-tolerated and produces a decrease in uKS and a trend toward improvement in growth."
The biomarker response supports reduction of the storage burden downstream of GALNS replacement.
Show evidence (4 references)
PMID:33256811 SUPPORT Human Clinical
"Early recognition, diagnosis, and treatment of this progressive, multisystem disease by enzyme replacement therapy (ERT) can lead to improved outcomes and reduced mortality."
This supports ERT as a disease-modifying Type A treatment with clinically meaningful outcome improvement.
PMID:33256811 SUPPORT Human Clinical
"All three patients demonstrated improvements in growth, 6-min walk distance, joint range of motion, and respiratory function after 30 months of ERT."
This gives disease-specific clinical evidence for improvement in mobility, growth, and respiratory function.
PMID:26331768 SUPPORT Human Clinical
"Early intervention with elosulfase alfa is well-tolerated and produces a decrease in uKS and a trend toward improvement in growth."
This supports biochemical and growth-related benefit when therapy is started early.
+ 1 more reference
Cervical decompression and fusion
Action: cervical decompression and fusion Ontology label: Spinal Fusion NCIT:C157986
Surgical stabilization of the craniovertebral junction is used when odontoid hypoplasia and atlantoaxial instability threaten the spinal cord.
Mechanism Target:
INHIBITS Craniovertebral instability — Decompression and fusion stabilize the upper cervical spine and inhibit ongoing craniovertebral instability.
Show evidence (1 reference)
PMID:29326877 SUPPORT Human Clinical
"Therefore, most patients require several surgeries to alleviate severe orthopedic complications, such as cervical spinal decompression and fusion, limb osteotomy, hemiepiphysiodesis, and hip reconstruction/replacement"
This directly links surgery to the craniovertebral instability branch.
INHIBITS Cervical spinal cord compression — Decompression relieves ongoing cervical cord compression risk.
Show evidence (1 reference)
PMID:29326877 SUPPORT Human Clinical
"Therefore, most patients require several surgeries to alleviate severe orthopedic complications, such as cervical spinal decompression and fusion, limb osteotomy, hemiepiphysiodesis, and hip reconstruction/replacement"
This directly links decompression surgery to the cervical spinal cord compression branch.
Show evidence (1 reference)
PMID:29326877 SUPPORT Human Clinical
"Therefore, most patients require several surgeries to alleviate severe orthopedic complications, such as cervical spinal decompression and fusion, limb osteotomy, hemiepiphysiodesis, and hip reconstruction/replacement"
This directly supports cervical decompression/fusion as standard management for severe Morquio skeletal complications.
Airway surgery for tracheal obstruction
Action: airway surgical procedure Ontology label: surgical procedure MAXO:0000004
Tracheal reconstructive procedures or tracheotomy may be required for life-threatening airway obstruction in severe disease.
Mechanism Target:
INHIBITS Structural airway narrowing — Airway surgery relieves the structural tracheal obstruction caused by Morquio airway disease.
Show evidence (2 references)
PMID:29326877 SUPPORT Human Clinical
"three patients with severe tracheal obstruction and respiratory distress showed improvement in their symptoms after undergoing successful tracheal reconstructive surgery"
Symptom improvement after reconstructive surgery supports direct inhibition of the structural airway-narrowing branch.
DOI:10.1186/s13023-024-03253-3 SUPPORT Human Clinical
"Postoperatively, significant improvements were seen in forced expiratory volume in 1 second (FEV1), with a mean increase of 0.68 litres (95% CI: 0.45-0.91; SD: 0.20)."
Objective postoperative spirometry improvement supports airway surgery as directly targeting the structural airway-narrowing branch.
Show evidence (3 references)
PMID:29326877 SUPPORT Human Clinical
"Tracheostomy has often been required for tracheal obstruction"
This directly supports airway surgery for severe Morquio tracheal obstruction.
PMID:29326877 SUPPORT Human Clinical
"three patients with severe tracheal obstruction and respiratory distress showed improvement in their symptoms after undergoing successful tracheal reconstructive surgery"
This provides direct evidence that reconstructive airway surgery can improve symptoms in severe Morquio airway disease.
DOI:10.1186/s13023-024-03253-3 SUPPORT Human Clinical
"Our findings demonstrate the effectiveness of the transcervical approach with partial manubriectomy for improving respiratory function and quality of life for individuals with advanced airway obstruction."
This 2024 case series supports tracheal resection with partial manubriectomy as an effective intervention for advanced Morquio A airway obstruction.
Physical therapy and mobility support
Action: physical therapy MAXO:0000011
Rehabilitation, pain control, and mobility aids help preserve function and reduce disability from chronic skeletal disease, even though they do not correct the underlying lysosomal defect.
Mechanism Target:
MODULATES Progressive skeletal dysplasia and joint laxity — Rehabilitation reduces secondary disability from chronic musculoskeletal disease without changing the upstream storage defect.
Show evidence (1 reference)
PMID:25346323 SUPPORT Other
"Physical therapy and pain medication can be beneficial to manage musculoskeletal manifestations in some patients."
This supports physical therapy as a symptomatic intervention for the skeletal disease branch.
Show evidence (1 reference)
PMID:25346323 SUPPORT Other
"Physical therapy and pain medication can be beneficial to manage musculoskeletal manifestations in some patients."
Guidelines directly support rehabilitation as part of symptomatic Morquio management.
🔬

Biochemical Markers

2
Keratan sulfate (Elevated)
Context: Core storage biomarker in blood and urine across Morquio syndrome, reflecting the shared keratan-sulfate disease axis.
Show evidence (1 reference)
PMID:25712379 SUPPORT Human Clinical
"The mean levels of both forms of KS in the plasma/serum from patients with MPS II, IVA, and IVB were elevated compared with that in age-matched controls."
This directly supports elevated keratan sulfate as a shared Morquio biochemical abnormality.
Chondroitin-6-sulfate (Elevated)
Context: Type A-specific GALNS substrate stored alongside keratan sulfate in cartilage and other connective tissues.
Show evidence (1 reference)
PMID:32905071 SUPPORT Human Clinical
"Consequently, partially degraded GAG, chondroitin 6-sulfate (CS) and keratan sulfate (KS), accumulate in the lysosomes of affected cells, primarily in cartilage resulting in skeletal disease."
This directly supports Type A storage of chondroitin-6-sulfate.
{ }

Source YAML

click to show 
name: Morquio syndrome
creation_date: '2026-04-14T19:54:40Z'
updated_date: '2026-05-10T14:54:51Z'
category: Mendelian
description: >-
  Morquio syndrome, or mucopolysaccharidosis type IV (MPS IV), is a lysosomal
  storage skeletal dysplasia caused by defective lysosomal degradation of
  keratan sulfate. Type A results from GALNS deficiency and causes storage of
  both keratan sulfate and chondroitin-6-sulfate, whereas Type B results from
  GLB1 deficiency with keratan-sulfate-dominant beta-galactosidase dysfunction.
  Storage in cartilage and other connective tissues disrupts chondrocyte
  biology, extracellular matrix organization, endochondral ossification, and
  ligament stability, producing short-trunk short stature, dysostosis
  multiplex, joint laxity, odontoid hypoplasia, cervical cord compression,
  airway obstruction, corneal clouding, hearing loss, and valve disease.
  Intelligence is usually preserved. Elosulfase alfa is disease-modifying for
  Type A, while both subtypes require intensive orthopedic, airway, and
  supportive management.
disease_term:
  preferred_term: Morquio syndrome
  term:
    id: MONDO:0018938
    label: mucopolysaccharidosis type 4
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0018938
      label: mucopolysaccharidosis type 4
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
parents:
- Mucopolysaccharidosis
- Lysosomal Storage Disorder
synonyms:
- Morquio disease
- mucopolysaccharidosis type IV
- MPS IV
has_subtypes:
- name: Type A
  display_name: Type A (MPS IVA, GALNS)
  subtype_term:
    preferred_term: Morquio syndrome A
    term:
      id: MONDO:0009659
      label: mucopolysaccharidosis type 4A
  description: >-
    GALNS-related Morquio syndrome with deficiency of
    N-acetylgalactosamine-6-sulfatase. Type A stores both keratan sulfate and
    chondroitin-6-sulfate and is the Morquio subtype for which elosulfase alfa
    enzyme replacement therapy is approved.
  evidence:
  - reference: PMID:32905071
    reference_title: Chondroitin sulfate disaccharide is a specific and sensitive biomarker for mucopolysaccharidosis type IVA.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mucopolysaccharidosis type IVA (MPS IVA) is an inborn error of glycosaminoglycan (GAG) catabolism characterized by a deficiency of the lysosomal enzyme, N-acetylgalactosamine 6-sulphatase (GALNS)."
    explanation: This directly defines Type A as the GALNS-deficient Morquio subtype.
  - reference: CGGV:assertion_c58d08e9-dc6d-45fc-a21a-54be3bc438d9-2022-06-16T040000.000Z
    reference_title: "GALNS / mucopolysaccharidosis type 4A (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GALNS | HGNC:4122 | mucopolysaccharidosis type 4A | MONDO:0009659 | AR | Definitive"
    explanation: >-
      ClinGen's Lysosomal Diseases GCEP classifies the GALNS-MPS IVA
      gene-disease relationship as Definitive with autosomal recessive
      inheritance.
- name: Type B
  display_name: Type B (MPS IVB, GLB1)
  subtype_term:
    preferred_term: Morquio syndrome B
    term:
      id: MONDO:0009660
      label: mucopolysaccharidosis type 4B
  description: >-
    GLB1-related Morquio syndrome with beta-galactosidase deficiency and
    keratan-sulfate-dominant storage. Type B is usually attenuated relative to
    Type A, although intermediate GLB1 phenotypes bridging GM1 gangliosidosis
    and Morquio B have been reported.
  evidence:
  - reference: PMID:33558080
    reference_title: "Morquio B disease: From pathophysiology towards diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Morquio B disease is an attenuated phenotype within the spectrum of beta galactosidase (GLB1) deficiencies."
    explanation: This directly defines Type B as a GLB1-related Morquio phenotype and supports retaining it as an explicit subtype.
  - reference: CGGV:assertion_9e170fda-e08a-4fd3-a3e5-f08c5c0d55b8-2023-04-28T160000.000Z
    reference_title: "GLB1 / mucopolysaccharidosis type 4B (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GLB1 | HGNC:4298 | mucopolysaccharidosis type 4B | MONDO:0009660 | AR | Definitive"
    explanation: >-
      ClinGen's Lysosomal Diseases GCEP classifies the GLB1-MPS IVB
      gene-disease relationship as Definitive with autosomal recessive
      inheritance.
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    Both Morquio subtypes are autosomal recessive lysosomal storage disorders.
  evidence:
  - reference: PMID:33256811
    reference_title: "Diagnostic journey and impact of enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mucopolysaccharidosis (MPS) IVA, also known as Morquio A syndrome, is a rare autosomal recessive lysosomal storage disorder caused by a deficiency in the enzyme N-acetylgalactosamine-6-sulfatase."
    explanation: This directly supports autosomal recessive inheritance for Type A.
  - reference: PMID:21497194
    reference_title: "GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "GM1 gangliosidosis and Morquio B are autosomal recessive storage disorders caused by the deficiency of β-galactosidase (GLB1), a lysosomal hydrolase that may be defective with respect to keratan sulfate (in Morquio B disease)"
    explanation: This directly supports autosomal recessive inheritance for Type B.
prevalence:
- subtype: Type A
  population: Reported incidence range
  notes: >-
    Published incidence estimates for Type A range from approximately
    1 in 640,000 live births in Western Australia to 1 in 76,000 in
    Northern Ireland.
  evidence:
  - reference: PMID:25346323
    reference_title: International guidelines for the management and treatment of Morquio A syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The disease is extremely rare, with incidence rates ranging from 1 in 640,000 live births in Western Australia to 1 in 76,000 live births in Northern Ireland"
    explanation: International guidelines summarize the published incidence range for Morquio A syndrome.
- subtype: Type B
  population: Reported incidence range
  notes: >-
    Type B is ultra-rare, with published incidence around 1:250,000 to
    1:1,000,000 live births.
  evidence:
  - reference: PMID:33558080
    reference_title: "Morquio B disease: From pathophysiology towards diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Morquio B disease, with an incidence of 1:250.000 to 1:1.000.000 live births, is very rare."
    explanation: This review/case series summarizes the reported incidence range for Morquio B disease.
progression:
- phase: Birth to early childhood
  subtype: Type A
  age_range: Birth to first years of life
  notes: >-
    Infants usually appear normal at birth, then progressively develop profound
    skeletal and joint abnormalities with additional non-skeletal involvement as
    storage accumulates.
  evidence:
  - reference: PMID:25346323
    reference_title: International guidelines for the management and treatment of Morquio A syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Infants with Morquio A syndrome usually appear normal at birth. However, due to the accumulation of storage material in tissues and organs, leading to cellular dysfunction, they progressively develop profound skeletal and joint abnormalities and an array of non-skeletal manifestations"
    explanation: This directly supports the typical normal-at-birth but progressive early-childhood natural history of Morquio A syndrome.
pathophysiology:
- name: Type A GALNS deficiency
  description: >-
    In Morquio type A, GALNS deficiency blocks lysosomal degradation of
    keratan sulfate and chondroitin-6-sulfate.
  genes:
  - preferred_term: GALNS
    term:
      id: hgnc:4122
      label: GALNS
  biological_processes:
  - preferred_term: glycosaminoglycan catabolic process
    modifier: DECREASED
    term:
      id: GO:0006027
      label: glycosaminoglycan catabolic process
  evidence:
  - reference: PMID:32905071
    reference_title: Chondroitin sulfate disaccharide is a specific and sensitive biomarker for mucopolysaccharidosis type IVA.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mucopolysaccharidosis type IVA (MPS IVA) is an inborn error of glycosaminoglycan (GAG) catabolism characterized by a deficiency of the lysosomal enzyme, N-acetylgalactosamine 6-sulphatase (GALNS)."
    explanation: This directly supports GALNS deficiency as the proximal defect in Type A disease.
  downstream:
  - target: Keratan sulfate-dominant lysosomal storage in cartilage and connective tissue
    causal_link_type: DIRECT
    description: Loss of GALNS activity causes lysosomal storage of keratan sulfate and chondroitin-6-sulfate in connective tissues.
    evidence:
    - reference: PMID:32905071
      reference_title: Chondroitin sulfate disaccharide is a specific and sensitive biomarker for mucopolysaccharidosis type IVA.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Consequently, partially degraded GAG, chondroitin 6-sulfate (CS) and keratan sulfate (KS), accumulate in the lysosomes of affected cells, primarily in cartilage resulting in skeletal disease."
      explanation: This directly links GALNS-related GAG catabolic failure in Type A to lysosomal CS/KS storage in cartilage.
- name: Type B GLB1 deficiency with keratan sulfate-biased catalytic loss
  description: >-
    In Morquio type B, GLB1 mutations create a beta-galactosidase deficiency
    phenotype in which keratan sulfate handling is disproportionately impaired,
    producing a skeletal/connective-tissue presentation rather than classic GM1
    gangliosidosis.
  genes:
  - preferred_term: GLB1
    term:
      id: hgnc:4298
      label: GLB1
  molecular_functions:
  - preferred_term: beta-galactosidase activity
    modifier: DECREASED
    term:
      id: GO:0004565
      label: beta-galactosidase activity
  evidence:
  - reference: PMID:21497194
    reference_title: "GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "GM1 gangliosidosis and Morquio B syndrome, both arising from beta-galactosidase (GLB1) deficiency, are very rare lysosomal storage diseases"
    explanation: This directly identifies GLB1 deficiency as the proximal lesion in Morquio B disease.
  - reference: PMID:12559848
    reference_title: Imbalanced substrate specificity of mutant beta-galactosidase in patients with Morquio B disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "These findings suggest that imbalanced substrate specificity of the mutant beta-Gals induces predominant accumulation of keratan sulfate and a rationale for performing differential diagnostic analysis for both disorders."
    explanation: Fibroblast kinetic studies show why GLB1-related Morquio disease is keratan-sulfate dominant rather than a generic beta-galactosidase phenotype.
  downstream:
  - target: Keratan sulfate-dominant lysosomal storage in cartilage and connective tissue
    causal_link_type: DIRECT
    description: GLB1 substrate imbalance produces keratan-sulfate-dominant storage in connective tissues.
    evidence:
    - reference: PMID:12559848
      reference_title: Imbalanced substrate specificity of mutant beta-galactosidase in patients with Morquio B disease.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "These findings suggest that imbalanced substrate specificity of the mutant beta-Gals induces predominant accumulation of keratan sulfate and a rationale for performing differential diagnostic analysis for both disorders."
      explanation: Fibroblast kinetic data support the edge from GLB1 substrate imbalance to predominant keratan sulfate storage in Morquio B.
- name: Keratan sulfate-dominant lysosomal storage in cartilage and connective tissue
  description: >-
    Keratan sulfate accumulates in both Morquio subtypes; Type A also stores
    chondroitin-6-sulfate. Storage is concentrated in cartilage and other
    connective tissues, where distended lysosomes initiate downstream tissue
    injury.
  cellular_components:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  cell_types:
  - preferred_term: chondrocyte
    term:
      id: CL:0000138
      label: chondrocyte
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  locations:
  - preferred_term: cartilage tissue
    term:
      id: UBERON:0002418
      label: cartilage tissue
  evidence:
  - reference: PMID:32905071
    reference_title: Chondroitin sulfate disaccharide is a specific and sensitive biomarker for mucopolysaccharidosis type IVA.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Consequently, partially degraded GAG, chondroitin 6-sulfate (CS) and keratan sulfate (KS), accumulate in the lysosomes of affected cells, primarily in cartilage resulting in skeletal disease."
    explanation: This directly supports the Type A storage node and cartilage-predominant tissue distribution.
  - reference: PMID:12559848
    reference_title: Imbalanced substrate specificity of mutant beta-galactosidase in patients with Morquio B disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "These findings suggest that imbalanced substrate specificity of the mutant beta-Gals induces predominant accumulation of keratan sulfate and a rationale for performing differential diagnostic analysis for both disorders."
    explanation: This provides subtype B support for the same keratan-sulfate-dominant storage node.
  downstream:
  - target: Cartilage matrix dysfunction and impaired endochondral ossification
    causal_link_type: DIRECT
    description: Storage distends chondrocytes and disrupts cartilage extracellular matrix and growth plate biology.
    evidence:
    - reference: PMID:29326877
      reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "As a result, partially degraded GAGs accumulate in bone, ligaments, and cartilage, as well as the extracellular matrix (ECM) of these tissues, impeding endochondral ossification and chondrogenesis"
      explanation: This human pathology review links GAG storage in cartilage, ligaments, and ECM to impaired endochondral ossification and chondrogenesis.
  - target: Corneal and valvular connective tissue involvement
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - glycosaminoglycan storage in non-skeletal connective tissues
    - corneal, auditory, and cardiac valve tissue dysfunction
    description: Storage extends beyond the skeleton to cornea and cardiac valves.
    evidence:
    - reference: PMID:25346323
      reference_title: International guidelines for the management and treatment of Morquio A syndrome.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Morquio A syndrome (mucopolysaccharidosis IVA) is a lysosomal storage disorder associated with skeletal and joint abnormalities and significant non-skeletal manifestations including respiratory disease, spinal cord compression, cardiac disease, impaired vision, hearing loss, and dental problems."
      explanation: Guidelines support non-skeletal manifestations downstream of lysosomal storage; the edge is indirect because the intermediate tissue-specific storage is compressed into this graph node.
- name: Cartilage matrix dysfunction and impaired endochondral ossification
  description: >-
    Glycosaminoglycan storage in cartilage, ligaments, and their extracellular
    matrix balloons chondrocytes and impedes endochondral ossification and
    chondrogenesis.
  cell_types:
  - preferred_term: growth plate cartilage chondrocyte
    term:
      id: CL:1000217
      label: growth plate cartilage chondrocyte
  locations:
  - preferred_term: growth plate cartilage
    term:
      id: UBERON:0004129
      label: growth plate cartilage
  - preferred_term: skeletal ligament
    term:
      id: UBERON:0008846
      label: skeletal ligament
  biological_processes:
  - preferred_term: endochondral ossification
    modifier: DECREASED
    term:
      id: GO:0001958
      label: endochondral ossification
  - preferred_term: cartilage development
    modifier: DECREASED
    term:
      id: GO:0051216
      label: cartilage development
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
  evidence:
  - reference: PMID:29326877
    reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "As a result, partially degraded GAGs accumulate in bone, ligaments, and cartilage, as well as the extracellular matrix (ECM) of these tissues, impeding endochondral ossification and chondrogenesis"
    explanation: This directly supplies the mechanistic bridge from storage to cartilage/connective-tissue dysfunction.
  - reference: PMID:29326877
    reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Examination of the tissues demonstrated systemic storage materials in multiple tissues, as well as severely ballooned and vacuolated chondrocytes in the trachea, humerus, knee cartilage, and lung bronchus."
    explanation: Human autopsy pathology confirms distorted chondrocyte morphology in multiple disease-relevant tissues.
  downstream:
  - target: Progressive skeletal dysplasia and joint laxity
    causal_link_type: DIRECT
    description: Defective cartilage and growth plate biology generates dysostosis multiplex, short stature, limb deformity, and joint laxity.
    evidence:
    - reference: PMID:29326877
      reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The accumulation of these GAGs leads to distinguishing features as skeletal dysplasia with disproportionate dwarfism, short neck, kyphoscoliosis, pectus carinatum, tracheal obstruction, coxa valga, genu valgum, and joint laxity."
      explanation: This directly connects accumulated GAGs and cartilage/connective-tissue disease with skeletal dysplasia and joint laxity.
- name: Progressive skeletal dysplasia and joint laxity
  description: >-
    Morquio syndrome expresses its core phenotype as progressive dysostosis
    multiplex, short stature, kyphoscoliosis, limb deformity, and joint laxity.
  evidence:
  - reference: PMID:29326877
    reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The accumulation of these GAGs leads to distinguishing features as skeletal dysplasia with disproportionate dwarfism, short neck, kyphoscoliosis, pectus carinatum, tracheal obstruction, coxa valga, genu valgum, and joint laxity."
    explanation: This directly supports the shared skeletal/connective-tissue phenotype cluster downstream of storage.
  - reference: PMID:32071837
    reference_title: "Morquio-B disease: Clinical and genetic characteristics of a distinct GLB1-related dysostosis multiplex."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Forty-one of 51 cases with informative clinical data had pure MBD including progressive growth impairment, kyphoscoliosis, coxa/genua valga, joint laxity, platyspondyly, odontoid hypoplasia."
    explanation: This extends the same skeletal/joint phenotype cluster explicitly into Morquio B disease.
  downstream:
  - target: Craniovertebral instability
    causal_link_type: DIRECT
    description: Odontoid hypoplasia and ligamentous laxity destabilize the craniovertebral junction.
    evidence:
    - reference: PMID:29326877
      reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Individuals with MPS IVA, particularly with the severe form, often do not survive past their twenties, as the most attributed causes of mortality and morbidity are spinal cord compression, instability of the C1-C2 joint, and airway compromise including tracheal obstruction"
      explanation: The autopsy/natural-history report links skeletal Morquio disease to C1-C2 instability and spinal cord compression.
  - target: Structural airway narrowing
    causal_link_type: DIRECT
    description: Skeletal chest/airway distortion and tracheal connective-tissue disease produce fixed airway narrowing.
    evidence:
    - reference: PMID:29326877
      reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The accumulation of these GAGs leads to distinguishing features as skeletal dysplasia with disproportionate dwarfism, short neck, kyphoscoliosis, pectus carinatum, tracheal obstruction, coxa valga, genu valgum, and joint laxity."
      explanation: This report lists tracheal obstruction in the same GAG-driven skeletal/connective-tissue disease cluster.
  - target: Dysostosis multiplex
    causal_link_type: DIRECT
    description: The progressive skeletal branch manifests clinically as dysostosis multiplex.
    evidence:
    - reference: PMID:33558080
      reference_title: "Morquio B disease: From pathophysiology towards diagnosis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "It is characterised by dysostosis multiplex, ligament laxity, mildly coarse facies and heart valve defects due to keratan sulphate accumulation, predominantly in the cartilage."
      explanation: This review explicitly connects cartilage-predominant keratan sulfate accumulation to dysostosis multiplex.
  - target: Short stature
    causal_link_type: DIRECT
    description: Impaired growth plate and skeletal development produce disproportionate short stature.
    evidence:
    - reference: PMID:29326877
      reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The accumulation of these GAGs leads to distinguishing features as skeletal dysplasia with disproportionate dwarfism, short neck, kyphoscoliosis, pectus carinatum, tracheal obstruction, coxa valga, genu valgum, and joint laxity."
      explanation: Disproportionate dwarfism is a direct clinical expression of the progressive skeletal dysplasia branch.
  - target: Pectus carinatum
    causal_link_type: DIRECT
    description: Thoracic skeletal dysplasia produces pectus carinatum.
    evidence:
    - reference: PMID:29326877
      reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The accumulation of these GAGs leads to distinguishing features as skeletal dysplasia with disproportionate dwarfism, short neck, kyphoscoliosis, pectus carinatum, tracheal obstruction, coxa valga, genu valgum, and joint laxity."
      explanation: Pectus carinatum is listed as a distinguishing skeletal feature downstream of GAG accumulation.
  - target: Genu valgum
    causal_link_type: DIRECT
    description: Lower-extremity skeletal dysplasia produces genu valgum.
    evidence:
    - reference: PMID:29326877
      reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The accumulation of these GAGs leads to distinguishing features as skeletal dysplasia with disproportionate dwarfism, short neck, kyphoscoliosis, pectus carinatum, tracheal obstruction, coxa valga, genu valgum, and joint laxity."
      explanation: Genu valgum is listed as a distinguishing skeletal feature downstream of GAG accumulation.
  - target: Joint laxity
    causal_link_type: DIRECT
    description: Ligament and joint connective-tissue disease manifests as joint laxity.
    evidence:
    - reference: PMID:29326877
      reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The accumulation of these GAGs leads to distinguishing features as skeletal dysplasia with disproportionate dwarfism, short neck, kyphoscoliosis, pectus carinatum, tracheal obstruction, coxa valga, genu valgum, and joint laxity."
      explanation: Joint laxity is listed as a distinguishing Morquio feature downstream of GAG accumulation.
  - target: Hypoplasia of the odontoid process
    causal_link_type: DIRECT
    description: Morquio skeletal dysplasia includes odontoid hypoplasia, which sets up craniovertebral instability.
    evidence:
    - reference: PMID:32071837
      reference_title: "Morquio-B disease: Clinical and genetic characteristics of a distinct GLB1-related dysostosis multiplex."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Forty-one of 51 cases with informative clinical data had pure MBD including progressive growth impairment, kyphoscoliosis, coxa/genua valga, joint laxity, platyspondyly, odontoid hypoplasia."
      explanation: This Morquio B cohort directly supports odontoid hypoplasia as part of the skeletal dysplasia branch.
- name: Craniovertebral instability
  description: >-
    Odontoid hypoplasia, atlantoaxial instability, and cervical canal narrowing
    destabilize the craniovertebral junction.
  locations:
  - preferred_term: atlanto-axial joint
    term:
      id: UBERON:0003694
      label: atlanto-axial joint
  evidence:
  - reference: PMID:29326877
    reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Individuals with MPS IVA, particularly with the severe form, often do not survive past their twenties, as the most attributed causes of mortality and morbidity are spinal cord compression, instability of the C1-C2 joint, and airway compromise including tracheal obstruction"
    explanation: This directly supports instability of the C1-C2 joint as a terminal high-risk Morquio mechanism.
  downstream:
  - target: Cervical spinal cord compression
    causal_link_type: DIRECT
    description: Craniovertebral instability and canal compromise threaten the cervical cord and can produce myelopathy.
    evidence:
    - reference: PMID:29326877
      reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Individuals with MPS IVA, particularly with the severe form, often do not survive past their twenties, as the most attributed causes of mortality and morbidity are spinal cord compression, instability of the C1-C2 joint, and airway compromise including tracheal obstruction"
      explanation: The mortality/morbidity statement directly couples C1-C2 instability with spinal cord compression.
- name: Cervical spinal cord compression
  description: >-
    Craniovertebral instability and cervical canal compromise can compress the
    cervical spinal cord and produce myelopathy.
  evidence:
  - reference: PMID:29326877
    reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Individuals with MPS IVA, particularly with the severe form, often do not survive past their twenties, as the most attributed causes of mortality and morbidity are spinal cord compression, instability of the C1-C2 joint, and airway compromise including tracheal obstruction"
    explanation: This directly supports cervical spinal cord compression as a terminal high-risk Morquio mechanism.
  - reference: PMID:32071837
    reference_title: "Morquio-B disease: Clinical and genetic characteristics of a distinct GLB1-related dysostosis multiplex."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Corneal clouding, cardiac valve pathology, hepatosplenomegaly, spinal cord compression were infrequent"
    explanation: This shows that spinal cord compression can occur in Type B, but should be framed as infrequent rather than core.
  downstream:
  - target: Spinal cord compression
    causal_link_type: DIRECT
    description: Cervical cord compression is the mechanism-level correlate of the spinal cord compression phenotype.
    evidence:
    - reference: PMID:29326877
      reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Individuals with MPS IVA, particularly with the severe form, often do not survive past their twenties, as the most attributed causes of mortality and morbidity are spinal cord compression, instability of the C1-C2 joint, and airway compromise including tracheal obstruction"
      explanation: The same clinical statement directly supports spinal cord compression as the phenotype endpoint of this branch.
- name: Structural airway narrowing
  description: >-
    Glycosaminoglycan-loaded tracheal cartilage together with thoracic and
    cervicothoracic skeletal distortion produces fixed upper-airway and
    tracheal narrowing.
  locations:
  - preferred_term: trachea
    term:
      id: UBERON:0003126
      label: trachea
  evidence:
  - reference: PMID:29326877
    reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This autopsied case with MPS IVA addresses the importance of tracheal obstruction for morbidity and mortality of the disease"
    explanation: This directly supports structural airway obstruction as a major Morquio mechanism.
  - reference: DOI:10.1186/s13023-024-03253-3
    reference_title: "Novel approach for tracheal resection in Morquio a syndrome with end-stage critical airway obstruction: a UK case series"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These manifestations of end-stage disease are engendered by an insidious progression of multi-level airway pathologies, comprising of tracheomalacia, stenosis, tortuosity and 'buckling'."
    explanation: This recent case series directly supports the structural, multi-level airway-narrowing mechanism in severe Morquio A.
  downstream:
  - target: Respiratory compromise
    causal_link_type: DIRECT
    description: Progressive fixed airway narrowing impairs ventilation and drives respiratory distress.
    evidence:
    - reference: PMID:29326877
      reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "three patients with severe tracheal obstruction and respiratory distress showed improvement in their symptoms after undergoing successful tracheal reconstructive surgery"
      explanation: Severe tracheal obstruction with respiratory distress supports the edge from structural airway narrowing to respiratory compromise.
  - target: Upper airway obstruction
    causal_link_type: DIRECT
    description: Fixed airway narrowing is clinically captured as upper-airway/tracheal obstruction.
    evidence:
    - reference: PMID:29326877
      reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This autopsied case with MPS IVA addresses the importance of tracheal obstruction for morbidity and mortality of the disease"
      explanation: This directly supports tracheal obstruction as the endpoint phenotype of the airway-narrowing branch.
- name: Respiratory compromise
  description: >-
    Progressive upper-airway and tracheal narrowing reduce ventilation and can
    lead to respiratory distress, chronic respiratory disease, and mortality.
  evidence:
  - reference: PMID:29326877
    reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Individuals with MPS IVA, particularly with the severe form, often do not survive past their twenties, as the most attributed causes of mortality and morbidity are spinal cord compression, instability of the C1-C2 joint, and airway compromise including tracheal obstruction"
    explanation: This directly supports respiratory compromise as a downstream consequence of Morquio airway disease.
  - reference: PMID:25346323
    reference_title: International guidelines for the management and treatment of Morquio A syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Morquio A syndrome (mucopolysaccharidosis IVA) is a lysosomal storage disorder associated with skeletal and joint abnormalities and significant non-skeletal manifestations including respiratory disease, spinal cord compression, cardiac disease, impaired vision, hearing loss, and dental problems."
    explanation: International guidelines confirm that respiratory disease is a central Morquio manifestation and should remain explicit in the pathograph.
- name: Corneal and valvular connective tissue involvement
  description: >-
    Storage outside cartilage affects cornea and cardiac valves, contributing to
    corneal clouding, impaired vision, hearing loss, and valve disease.
  locations:
  - preferred_term: cornea
    term:
      id: UBERON:0000964
      label: cornea
  - preferred_term: cardiac valve
    term:
      id: UBERON:0000946
      label: cardiac valve
  evidence:
  - reference: PMID:25346323
    reference_title: International guidelines for the management and treatment of Morquio A syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Morquio A syndrome (mucopolysaccharidosis IVA) is a lysosomal storage disorder associated with skeletal and joint abnormalities and significant non-skeletal manifestations including respiratory disease, spinal cord compression, cardiac disease, impaired vision, hearing loss, and dental problems."
    explanation: This supports a non-skeletal connective-tissue branch involving vision, hearing, and cardiac disease.
  - reference: PMID:33558080
    reference_title: "Morquio B disease: From pathophysiology towards diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is characterised by dysostosis multiplex, ligament laxity, mildly coarse facies and heart valve defects due to keratan sulphate accumulation, predominantly in the cartilage."
    explanation: This extends the same connective-tissue branch into Morquio B with explicit heart valve involvement.
  downstream:
  - target: Corneal opacity
    causal_link_type: DIRECT
    description: Corneal connective-tissue involvement manifests as corneal clouding/opacity.
    evidence:
    - reference: PMID:29054894
      reference_title: "Mucopolysaccharidosis type IVA (Morquio A): a close differential diagnosis of spondylo-epiphyseal dysplasia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "MPS type IVA (Morquio A syndrome) has predominant musculoskeletal system involvement and corneal clouding with normal intelligence and can be misdiagnosed as primary skeletal disorders in clinical practice."
      explanation: This directly supports corneal clouding as an endpoint of the extra-skeletal connective-tissue branch.
  - target: Hearing abnormality
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - otolaryngologic and middle-ear involvement in Morquio syndrome
    description: Extra-skeletal craniofacial and ENT involvement contributes to hearing loss.
    evidence:
    - reference: PMID:25346323
      reference_title: International guidelines for the management and treatment of Morquio A syndrome.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Morquio A syndrome (mucopolysaccharidosis IVA) is a lysosomal storage disorder associated with skeletal and joint abnormalities and significant non-skeletal manifestations including respiratory disease, spinal cord compression, cardiac disease, impaired vision, hearing loss, and dental problems."
      explanation: Guidelines support hearing loss as a significant non-skeletal manifestation; the edge is indirect because the auditory intermediate is not separately modeled.
  - target: Abnormal heart valve morphology
    causal_link_type: DIRECT
    description: Valvular connective-tissue involvement manifests as abnormal cardiac valve morphology.
    evidence:
    - reference: PMID:33558080
      reference_title: "Morquio B disease: From pathophysiology towards diagnosis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "It is characterised by dysostosis multiplex, ligament laxity, mildly coarse facies and heart valve defects due to keratan sulphate accumulation, predominantly in the cartilage."
      explanation: This directly connects keratan sulfate-associated Morquio connective-tissue involvement with heart valve defects.
phenotypes:
- name: Dysostosis multiplex
  category: Skeletal
  description: >-
    Morquio syndrome produces a progressive dysostosis multiplex pattern with
    vertebral, thoracic, and appendicular skeletal deformity.
  phenotype_term:
    preferred_term: Dysostosis multiplex
    term:
      id: HP:0000943
      label: Dysostosis multiplex
  evidence:
  - reference: PMID:33558080
    reference_title: "Morquio B disease: From pathophysiology towards diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is characterised by dysostosis multiplex, ligament laxity, mildly coarse facies and heart valve defects due to keratan sulphate accumulation, predominantly in the cartilage."
    explanation: This directly identifies dysostosis multiplex as a defining Morquio phenotype.
- name: Short stature
  category: Growth
  description: >-
    Disproportionate short stature results from impaired endochondral bone
    growth and progressive skeletal dysplasia.
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: PMID:29326877
    reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The accumulation of these GAGs leads to distinguishing features as skeletal dysplasia with disproportionate dwarfism, short neck, kyphoscoliosis, pectus carinatum, tracheal obstruction, coxa valga, genu valgum, and joint laxity."
    explanation: Disproportionate dwarfism directly supports short stature as a core Morquio phenotype.
- name: Pectus carinatum
  category: Skeletal
  description: >-
    Chest wall deformity is a common skeletal manifestation of Morquio syndrome.
  phenotype_term:
    preferred_term: Pectus carinatum
    term:
      id: HP:0000768
      label: Pectus carinatum
  evidence:
  - reference: PMID:29326877
    reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The accumulation of these GAGs leads to distinguishing features as skeletal dysplasia with disproportionate dwarfism, short neck, kyphoscoliosis, pectus carinatum, tracheal obstruction, coxa valga, genu valgum, and joint laxity."
    explanation: This directly lists pectus carinatum among the distinguishing Morquio skeletal features.
- name: Genu valgum
  category: Skeletal
  description: >-
    Valgus deformity of the knees is a common lower-extremity consequence of
    Morquio skeletal dysplasia.
  phenotype_term:
    preferred_term: Genu valgum
    term:
      id: HP:0002857
      label: Genu valgum
  evidence:
  - reference: PMID:29326877
    reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The accumulation of these GAGs leads to distinguishing features as skeletal dysplasia with disproportionate dwarfism, short neck, kyphoscoliosis, pectus carinatum, tracheal obstruction, coxa valga, genu valgum, and joint laxity."
    explanation: This directly lists genu valgum as a distinguishing skeletal manifestation.
- name: Joint laxity
  category: Skeletal
  description: >-
    Joint laxity distinguishes Morquio syndrome from many other
    mucopolysaccharidoses, which more often cause joint stiffness.
  phenotype_term:
    preferred_term: Joint laxity
    term:
      id: HP:0001382
      label: Joint hypermobility
  evidence:
  - reference: PMID:29326877
    reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The accumulation of these GAGs leads to distinguishing features as skeletal dysplasia with disproportionate dwarfism, short neck, kyphoscoliosis, pectus carinatum, tracheal obstruction, coxa valga, genu valgum, and joint laxity."
    explanation: This directly lists joint laxity as a distinguishing Morquio manifestation.
  - reference: PMID:32071837
    reference_title: "Morquio-B disease: Clinical and genetic characteristics of a distinct GLB1-related dysostosis multiplex."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Forty-one of 51 cases with informative clinical data had pure MBD including progressive growth impairment, kyphoscoliosis, coxa/genua valga, joint laxity, platyspondyly, odontoid hypoplasia."
    explanation: This confirms joint laxity also belongs to the Morquio B phenotype.
- name: Hypoplasia of the odontoid process
  category: Skeletal
  description: >-
    Odontoid hypoplasia contributes to craniovertebral instability and risk of
    cervical cord compromise.
  phenotype_term:
    preferred_term: Hypoplasia of the odontoid process
    term:
      id: HP:0003311
      label: Hypoplasia of the odontoid process
  evidence:
  - reference: PMID:32071837
    reference_title: "Morquio-B disease: Clinical and genetic characteristics of a distinct GLB1-related dysostosis multiplex."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Forty-one of 51 cases with informative clinical data had pure MBD including progressive growth impairment, kyphoscoliosis, coxa/genua valga, joint laxity, platyspondyly, odontoid hypoplasia."
    explanation: This directly supports odontoid hypoplasia as a Morquio skeletal phenotype.
  - reference: PMID:8233358
    reference_title: Cataracts in Morquio syndrome (mucopolysaccharidosis IV A).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In addition to the characteristic dwarfism with skeletal deformities, odontoid anomalies, hearing loss and corneal clouding, the authors found almost identical lens opacities in all three patients."
    explanation: This confirms odontoid anomalies in Type A disease as well.
- name: Spinal cord compression
  category: Neurologic
  subtype: Type A
  description: >-
    Cervical instability and canal compromise can produce clinically significant
    spinal cord compression and myelopathy, especially in severe Type A disease.
  phenotype_term:
    preferred_term: Spinal cord compression
    term:
      id: HP:0002176
      label: Spinal cord compression
  evidence:
  - reference: PMID:29326877
    reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Individuals with MPS IVA, particularly with the severe form, often do not survive past their twenties, as the most attributed causes of mortality and morbidity are spinal cord compression, instability of the C1-C2 joint, and airway compromise including tracheal obstruction"
    explanation: This directly supports spinal cord compression as a severe Type A complication.
- name: Upper airway obstruction
  category: Respiratory
  subtype: Type A
  description: >-
    Tracheal and upper-airway narrowing contribute to progressive respiratory
    compromise and procedure-related airway risk.
  phenotype_term:
    preferred_term: Upper airway obstruction
    term:
      id: HP:0002781
      label: Upper airway obstruction
  evidence:
  - reference: PMID:29326877
    reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This autopsied case with MPS IVA addresses the importance of tracheal obstruction for morbidity and mortality of the disease"
    explanation: This directly supports life-limiting airway obstruction in severe Morquio A syndrome.
- name: Corneal opacity
  category: Ophthalmic
  description: >-
    Corneal clouding is a characteristic extra-skeletal manifestation of Morquio
    syndrome.
  phenotype_term:
    preferred_term: Corneal opacity
    term:
      id: HP:0007957
      label: Corneal opacity
  evidence:
  - reference: PMID:29054894
    reference_title: "Mucopolysaccharidosis type IVA (Morquio A): a close differential diagnosis of spondylo-epiphyseal dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MPS type IVA (Morquio A syndrome) has predominant musculoskeletal system involvement and corneal clouding with normal intelligence and can be misdiagnosed as primary skeletal disorders in clinical practice."
    explanation: This directly supports corneal clouding as a core Type A feature.
  - reference: PMID:8233358
    reference_title: Cataracts in Morquio syndrome (mucopolysaccharidosis IV A).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In addition to the characteristic dwarfism with skeletal deformities, odontoid anomalies, hearing loss and corneal clouding, the authors found almost identical lens opacities in all three patients."
    explanation: This independently confirms corneal clouding in Type A disease.
- name: Hearing abnormality
  category: Otolaryngologic
  description: >-
    Hearing loss is a recurrent Morquio manifestation that travels with the
    extra-skeletal connective-tissue disease burden.
  phenotype_term:
    preferred_term: Hearing abnormality
    term:
      id: HP:0000364
      label: Hearing abnormality
  evidence:
  - reference: PMID:25346323
    reference_title: International guidelines for the management and treatment of Morquio A syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Morquio A syndrome (mucopolysaccharidosis IVA) is a lysosomal storage disorder associated with skeletal and joint abnormalities and significant non-skeletal manifestations including respiratory disease, spinal cord compression, cardiac disease, impaired vision, hearing loss, and dental problems."
    explanation: Guidelines explicitly include hearing loss among the significant non-skeletal manifestations of Morquio A.
  - reference: PMID:8233358
    reference_title: Cataracts in Morquio syndrome (mucopolysaccharidosis IV A).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In addition to the characteristic dwarfism with skeletal deformities, odontoid anomalies, hearing loss and corneal clouding, the authors found almost identical lens opacities in all three patients."
    explanation: This provides direct patient-level support for hearing loss in Morquio syndrome.
- name: Abnormal heart valve morphology
  category: Cardiac
  description: >-
    Cardiac valve disease belongs to the extra-skeletal connective-tissue
    involvement of Morquio syndrome and is well described in both subtypes.
  phenotype_term:
    preferred_term: Abnormal heart valve morphology
    term:
      id: HP:0001654
      label: Abnormal heart valve morphology
  evidence:
  - reference: PMID:25346323
    reference_title: International guidelines for the management and treatment of Morquio A syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Morquio A syndrome (mucopolysaccharidosis IVA) is a lysosomal storage disorder associated with skeletal and joint abnormalities and significant non-skeletal manifestations including respiratory disease, spinal cord compression, cardiac disease, impaired vision, hearing loss, and dental problems."
    explanation: Guidelines explicitly include cardiac disease among the major Morquio A manifestations.
  - reference: PMID:33558080
    reference_title: "Morquio B disease: From pathophysiology towards diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is characterised by dysostosis multiplex, ligament laxity, mildly coarse facies and heart valve defects due to keratan sulphate accumulation, predominantly in the cartilage."
    explanation: This directly supports heart valve disease in Morquio B.
biochemical:
- name: Keratan sulfate
  presence: Elevated
  context: >-
    Core storage biomarker in blood and urine across Morquio syndrome,
    reflecting the shared keratan-sulfate disease axis.
  evidence:
  - reference: PMID:25712379
    reference_title: Di-sulfated Keratan Sulfate as a Novel Biomarker for Mucopolysaccharidosis II, IVA, and IVB.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mean levels of both forms of KS in the plasma/serum from patients with MPS II, IVA, and IVB were elevated compared with that in age-matched controls."
    explanation: This directly supports elevated keratan sulfate as a shared Morquio biochemical abnormality.
- name: Chondroitin-6-sulfate
  subtype: Type A
  presence: Elevated
  context: >-
    Type A-specific GALNS substrate stored alongside keratan sulfate in
    cartilage and other connective tissues.
  evidence:
  - reference: PMID:32905071
    reference_title: Chondroitin sulfate disaccharide is a specific and sensitive biomarker for mucopolysaccharidosis type IVA.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Consequently, partially degraded GAG, chondroitin 6-sulfate (CS) and keratan sulfate (KS), accumulate in the lysosomes of affected cells, primarily in cartilage resulting in skeletal disease."
    explanation: This directly supports Type A storage of chondroitin-6-sulfate.
genetic:
- name: GALNS
  gene_term:
    preferred_term: GALNS
    term:
      id: hgnc:4122
      label: GALNS
  association: Causative
  subtype: Type A
  notes: >-
    Definitive Type A disease gene in ClinGen and the proximal enzymatic lesion
    of Morquio A syndrome.
  evidence:
  - reference: PMID:32905071
    reference_title: Chondroitin sulfate disaccharide is a specific and sensitive biomarker for mucopolysaccharidosis type IVA.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mucopolysaccharidosis type IVA (MPS IVA) is an inborn error of glycosaminoglycan (GAG) catabolism characterized by a deficiency of the lysosomal enzyme, N-acetylgalactosamine 6-sulphatase (GALNS)."
    explanation: This directly identifies GALNS as the causative gene/enzyme in Type A disease.
- name: GLB1
  gene_term:
    preferred_term: GLB1
    term:
      id: hgnc:4298
      label: GLB1
  association: Causative
  subtype: Type B
  notes: >-
    Definitive Type B disease gene in ClinGen. GLB1 deficiency spans Morquio B
    and GM1 gangliosidosis phenotypes, but Morquio B is retained here as the
    keratan-sulfate-dominant dysostosis multiplex subtype.
  evidence:
  - reference: PMID:21497194
    reference_title: "GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "GM1 gangliosidosis and Morquio B syndrome, both arising from beta-galactosidase (GLB1) deficiency, are very rare lysosomal storage diseases"
    explanation: This directly supports GLB1 as the causative gene for Morquio B disease.
  - reference: PMID:33558080
    reference_title: "Morquio B disease: From pathophysiology towards diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Morquio B disease is an attenuated phenotype within the spectrum of beta galactosidase (GLB1) deficiencies."
    explanation: This supports retaining GLB1-related Morquio disease as an explicit Type B subtype.
treatments:
- name: Type A elosulfase alfa enzyme replacement therapy
  description: >-
    Weekly intravenous recombinant GALNS replaces the deficient Type A enzyme,
    lowers storage biomarkers, and improves endurance, respiratory function, and
    growth-related outcomes. Skeletal, tracheal, and ocular tissues remain only
    partially responsive because of limited penetration.
  treatment_term:
    preferred_term: enzyme replacement therapy
    term:
      id: MAXO:0000933
      label: enzyme replacement or supplementation therapy
  evidence:
  - reference: PMID:33256811
    reference_title: "Diagnostic journey and impact of enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early recognition, diagnosis, and treatment of this progressive, multisystem disease by enzyme replacement therapy (ERT) can lead to improved outcomes and reduced mortality."
    explanation: This supports ERT as a disease-modifying Type A treatment with clinically meaningful outcome improvement.
  - reference: PMID:33256811
    reference_title: "Diagnostic journey and impact of enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All three patients demonstrated improvements in growth, 6-min walk distance, joint range of motion, and respiratory function after 30 months of ERT."
    explanation: This gives disease-specific clinical evidence for improvement in mobility, growth, and respiratory function.
  - reference: PMID:26331768
    reference_title: Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early intervention with elosulfase alfa is well-tolerated and produces a decrease in uKS and a trend toward improvement in growth."
    explanation: This supports biochemical and growth-related benefit when therapy is started early.
  - reference: PMID:30442189
    reference_title: "Enzyme replacement therapy: efficacy and limitations."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "While ERT is effective in reducing urinary glycosaminoglycans (GAGs) and liver and spleen volume, cartilaginous organs such as the trachea and bronchi, bones and eyes are poorly impacted by ERT probably due to limited penetration in the specific tissue."
    explanation: This keeps the limitation statement honest for bone, airway, and ocular disease.
  target_mechanisms:
  - target: Type A GALNS deficiency
    treatment_effect: RESTORES
    description: Recombinant GALNS replaces the missing lysosomal enzyme in Type A disease.
    evidence:
    - reference: PMID:26331768
      reference_title: Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Early intervention with elosulfase alfa is well-tolerated and produces a decrease in uKS and a trend toward improvement in growth."
      explanation: Lower uKS with clinical improvement supports restoration of proximal Type A enzymatic function.
  - target: Keratan sulfate-dominant lysosomal storage in cartilage and connective tissue
    treatment_effect: INHIBITS
    description: Lower urinary keratan sulfate indicates partial suppression of the systemic storage burden.
    evidence:
    - reference: PMID:26331768
      reference_title: Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Early intervention with elosulfase alfa is well-tolerated and produces a decrease in uKS and a trend toward improvement in growth."
      explanation: The biomarker response supports reduction of the storage burden downstream of GALNS replacement.
- name: Cervical decompression and fusion
  description: >-
    Surgical stabilization of the craniovertebral junction is used when odontoid
    hypoplasia and atlantoaxial instability threaten the spinal cord.
  treatment_term:
    preferred_term: cervical decompression and fusion
    term:
      id: NCIT:C157986
      label: Spinal Fusion
  evidence:
  - reference: PMID:29326877
    reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Therefore, most patients require several surgeries to alleviate severe orthopedic complications, such as cervical spinal decompression and fusion, limb osteotomy, hemiepiphysiodesis, and hip reconstruction/replacement"
    explanation: This directly supports cervical decompression/fusion as standard management for severe Morquio skeletal complications.
  target_mechanisms:
  - target: Craniovertebral instability
    treatment_effect: INHIBITS
    description: Decompression and fusion stabilize the upper cervical spine and inhibit ongoing craniovertebral instability.
    evidence:
    - reference: PMID:29326877
      reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Therefore, most patients require several surgeries to alleviate severe orthopedic complications, such as cervical spinal decompression and fusion, limb osteotomy, hemiepiphysiodesis, and hip reconstruction/replacement"
      explanation: This directly links surgery to the craniovertebral instability branch.
  - target: Cervical spinal cord compression
    treatment_effect: INHIBITS
    description: Decompression relieves ongoing cervical cord compression risk.
    evidence:
    - reference: PMID:29326877
      reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Therefore, most patients require several surgeries to alleviate severe orthopedic complications, such as cervical spinal decompression and fusion, limb osteotomy, hemiepiphysiodesis, and hip reconstruction/replacement"
      explanation: This directly links decompression surgery to the cervical spinal cord compression branch.
- name: Airway surgery for tracheal obstruction
  description: >-
    Tracheal reconstructive procedures or tracheotomy may be required for
    life-threatening airway obstruction in severe disease.
  treatment_term:
    preferred_term: airway surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  evidence:
  - reference: PMID:29326877
    reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Tracheostomy has often been required for tracheal obstruction"
    explanation: This directly supports airway surgery for severe Morquio tracheal obstruction.
  - reference: PMID:29326877
    reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "three patients with severe tracheal obstruction and respiratory distress showed improvement in their symptoms after undergoing successful tracheal reconstructive surgery"
    explanation: This provides direct evidence that reconstructive airway surgery can improve symptoms in severe Morquio airway disease.
  - reference: DOI:10.1186/s13023-024-03253-3
    reference_title: "Novel approach for tracheal resection in Morquio a syndrome with end-stage critical airway obstruction: a UK case series"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our findings demonstrate the effectiveness of the transcervical approach with partial manubriectomy for improving respiratory function and quality of life for individuals with advanced airway obstruction."
    explanation: This 2024 case series supports tracheal resection with partial manubriectomy as an effective intervention for advanced Morquio A airway obstruction.
  target_mechanisms:
  - target: Structural airway narrowing
    treatment_effect: INHIBITS
    description: Airway surgery relieves the structural tracheal obstruction caused by Morquio airway disease.
    evidence:
    - reference: PMID:29326877
      reference_title: Natural history of Morquio A patient with tracheal obstruction from birth to death.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "three patients with severe tracheal obstruction and respiratory distress showed improvement in their symptoms after undergoing successful tracheal reconstructive surgery"
      explanation: Symptom improvement after reconstructive surgery supports direct inhibition of the structural airway-narrowing branch.
    - reference: DOI:10.1186/s13023-024-03253-3
      reference_title: "Novel approach for tracheal resection in Morquio a syndrome with end-stage critical airway obstruction: a UK case series"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Postoperatively, significant improvements were seen in forced expiratory volume in 1 second (FEV1), with a mean increase of 0.68 litres (95% CI: 0.45-0.91; SD: 0.20)."
      explanation: Objective postoperative spirometry improvement supports airway surgery as directly targeting the structural airway-narrowing branch.
- name: Physical therapy and mobility support
  description: >-
    Rehabilitation, pain control, and mobility aids help preserve function and
    reduce disability from chronic skeletal disease, even though they do not
    correct the underlying lysosomal defect.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
  evidence:
  - reference: PMID:25346323
    reference_title: International guidelines for the management and treatment of Morquio A syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Physical therapy and pain medication can be beneficial to manage musculoskeletal manifestations in some patients."
    explanation: Guidelines directly support rehabilitation as part of symptomatic Morquio management.
  target_mechanisms:
  - target: Progressive skeletal dysplasia and joint laxity
    treatment_effect: MODULATES
    description: Rehabilitation reduces secondary disability from chronic musculoskeletal disease without changing the upstream storage defect.
    evidence:
    - reference: PMID:25346323
      reference_title: International guidelines for the management and treatment of Morquio A syndrome.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Physical therapy and pain medication can be beneficial to manage musculoskeletal manifestations in some patients."
      explanation: This supports physical therapy as a symptomatic intervention for the skeletal disease branch.
references:
- reference: DOI:10.1016/j.omtm.2024.101313
  title: A GLB1 transgene with enhanced therapeutic potential for the preclinical development of ex-vivo gene therapy to treat mucopolysaccharidosis type IVB
  found_in:
  - Morquio_syndrome-deep-research-falcon.md
  findings:
  - statement: A GLB1 transgene with enhanced therapeutic potential for the preclinical development of ex-vivo gene therapy to treat mucopolysaccharidosis type IVB
    supporting_text: A GLB1 transgene with enhanced therapeutic potential for the preclinical development of ex-vivo gene therapy to treat mucopolysaccharidosis type IVB
    evidence:
    - reference: PMID:39282079
      reference_title: A GLB1 transgene with enhanced therapeutic potential for the preclinical development of ex-vivo gene therapy to treat mucopolysaccharidosis type IVB.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: These results support the use of LV-enhGLB1 for further HSPC-GT development and future clinical translation to treat MPSIVB multisystem disease.
      explanation: Preclinical HSPC gene therapy study in which LV-enhGLB1-transduced human HSPCs were validated in vivo (mouse transplantation), supporting an enhanced GLB1 transgene as a candidate ex-vivo gene therapy for MPS IVB.
- reference: DOI:10.1016/j.omtn.2024.102211
  title: Adeno-associated virus-based gene therapy delivering combinations of two growth-associated genes to MPS IVA mice
  found_in:
  - Morquio_syndrome-deep-research-falcon.md
  findings:
  - statement: Adeno-associated virus-based gene therapy delivering combinations of two growth-associated genes to MPS IVA mice
    supporting_text: Adeno-associated virus-based gene therapy delivering combinations of two growth-associated genes to MPS IVA mice
    evidence:
    - reference: PMID:38831899
      reference_title: Molecular therapy and nucleic acid adeno-associated virus-based gene therapy delivering combinations of two growth-associated genes to MPS IVA mice.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Delivering combinations of CNP and GALNS gene therapies enhanced bone growth in MPS IVA mice more than in GALNS gene therapy alone.
      explanation: MPS IVA mouse model study supporting AAV combination gene therapy (GALNS + CNP) for enhanced bone growth versus GALNS gene therapy alone.
- reference: DOI:10.1186/s13023-019-1074-9
  title: 'Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance'
  found_in:
  - Morquio_syndrome-deep-research-falcon.md
  findings:
  - statement: 'Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance'
    supporting_text: 'Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance'
    evidence:
    - reference: PMID:31196221
      reference_title: 'Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: This manuscript provides evidence- and consensus-based recommendations for the management of patients with MPS IVA and is for use by healthcare professionals that manage the holistic care of patients with the intention to improve clinical- and patient-reported outcomes and enhance patient quality of life.
      explanation: International expert consensus and evidence-based recommendations for the management of patients with MPS IVA.
- reference: DOI:10.1186/s13023-021-01675-x
  title: 'Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type IVA: results from a Managed Access Agreement in England'
  found_in:
  - Morquio_syndrome-deep-research-falcon.md
  findings:
  - statement: 'Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type IVA: results from a Managed Access Agreement in England'
    supporting_text: We present baseline characteristics and follow-up data of a Managed Access Agreement (MAA), including patients with mucopolysaccharidosis IVA (MPS IVA) receiving elosulfase alfa enzyme replacement therapy (ERT) in England on a conditional basis.
    evidence:
    - reference: DOI:10.1186/s13023-021-01675-x
      reference_title: 'Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type IVA: results from a Managed Access Agreement in England'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: We present baseline characteristics and follow-up data of a Managed Access Agreement (MAA), including patients with mucopolysaccharidosis IVA (MPS IVA) receiving elosulfase alfa enzyme replacement therapy (ERT) in England on a conditional basis.
      explanation: Deep research cited this publication as relevant literature for Morquio syndrome.
- reference: DOI:10.1186/s13023-021-02074-y
  title: 'Clinical features and health-related quality of life in adult patients with mucopolysaccharidosis IVA: the Spanish experience'
  found_in:
  - Morquio_syndrome-deep-research-falcon.md
  findings:
  - statement: Mucopolysaccharidosis (MPS) IVA or Morquio A syndrome is a progressive and disabling disease characterized by a deficiency of the enzyme N-acetylgalactosamine-6-sulphate sulphatase.
    supporting_text: Mucopolysaccharidosis (MPS) IVA or Morquio A syndrome is a progressive and disabling disease characterized by a deficiency of the enzyme N-acetylgalactosamine-6-sulphate sulphatase.
    evidence:
    - reference: DOI:10.1186/s13023-021-02074-y
      reference_title: 'Clinical features and health-related quality of life in adult patients with mucopolysaccharidosis IVA: the Spanish experience'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Mucopolysaccharidosis (MPS) IVA or Morquio A syndrome is a progressive and disabling disease characterized by a deficiency of the enzyme N-acetylgalactosamine-6-sulphate sulphatase.
      explanation: Deep research cited this publication as relevant literature for Morquio syndrome.
- reference: DOI:10.1186/s13023-022-02332-7
  title: Consensus statement on enzyme replacement therapy for mucopolysaccharidosis IVA in Central and South-Eastern European countries
  found_in:
  - Morquio_syndrome-deep-research-falcon.md
  findings:
  - statement: Mucopolysaccharidosis IVA (MPS IVA), or Morquio A syndrome, is a rare inherited metabolic disorder caused by deficiency of the lysosomal enzyme N-acetylgalactosamine-6-sulfatase.
    supporting_text: Mucopolysaccharidosis IVA (MPS IVA), or Morquio A syndrome, is a rare inherited metabolic disorder caused by deficiency of the lysosomal enzyme N-acetylgalactosamine-6-sulfatase.
    evidence:
    - reference: DOI:10.1186/s13023-022-02332-7
      reference_title: Consensus statement on enzyme replacement therapy for mucopolysaccharidosis IVA in Central and South-Eastern European countries
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Mucopolysaccharidosis IVA (MPS IVA), or Morquio A syndrome, is a rare inherited metabolic disorder caused by deficiency of the lysosomal enzyme N-acetylgalactosamine-6-sulfatase.
      explanation: Deep research cited this publication as relevant literature for Morquio syndrome.
- reference: DOI:10.1186/s13023-024-03237-3
  title: Consensus-based expert recommendations on the management of MPS IVa and VI in Saudi Arabia
  found_in:
  - Morquio_syndrome-deep-research-falcon.md
  findings:
  - statement: Consensus-based expert recommendations on the management of MPS IVa and VI in Saudi Arabia
    supporting_text: Mucopolysaccharidosis type IVa (Morquio A syndrome) and mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome) are rare inherited lysosomal storage diseases associated with significant functional impairment and a wide spectrum of debilitating clinical manifestations.
    evidence:
    - reference: DOI:10.1186/s13023-024-03237-3
      reference_title: Consensus-based expert recommendations on the management of MPS IVa and VI in Saudi Arabia
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Mucopolysaccharidosis type IVa (Morquio A syndrome) and mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome) are rare inherited lysosomal storage diseases associated with significant functional impairment and a wide spectrum of debilitating clinical manifestations.
      explanation: Deep research cited this publication as relevant literature for Morquio syndrome.
- reference: DOI:10.1186/s13023-024-03253-3
  title: 'Novel approach for tracheal resection in Morquio a syndrome with end-stage critical airway obstruction: a UK case series'
  found_in:
  - Morquio_syndrome-deep-research-falcon.md
  findings:
  - statement: Mucopolysaccharidosis (MPS) type IVA is a rare lysosomal storage disorder caused by aberrations of the N-acetyl-galactosamine-6-sulfatase (GALNS) enzyme.
    supporting_text: Mucopolysaccharidosis (MPS) type IVA is a rare lysosomal storage disorder caused by aberrations of the N-acetyl-galactosamine-6-sulfatase (GALNS) enzyme.
    evidence:
    - reference: DOI:10.1186/s13023-024-03253-3
      reference_title: 'Novel approach for tracheal resection in Morquio a syndrome with end-stage critical airway obstruction: a UK case series'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Mucopolysaccharidosis (MPS) type IVA is a rare lysosomal storage disorder caused by aberrations of the N-acetyl-galactosamine-6-sulfatase (GALNS) enzyme.
      explanation: Deep research cited this publication as relevant literature for Morquio syndrome.
- reference: DOI:10.3389/fgene.2024.1343094
  title: Identification of new variants in patients with mucopolysaccharidosis in consanguineous Iranian families
  found_in:
  - Morquio_syndrome-deep-research-falcon.md
  findings:
  - statement: Mucopolysaccharidoses are a group of lysosomal storage disorders that include seven types that are classified based on the enzymes that are disrupted.
    supporting_text: Mucopolysaccharidoses are a group of lysosomal storage disorders that include seven types that are classified based on the enzymes that are disrupted.
    evidence:
    - reference: DOI:10.3389/fgene.2024.1343094
      reference_title: Identification of new variants in patients with mucopolysaccharidosis in consanguineous Iranian families
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Mucopolysaccharidoses are a group of lysosomal storage disorders that include seven types that are classified based on the enzymes that are disrupted.
      explanation: Deep research cited this publication as relevant literature for Morquio syndrome.
- reference: DOI:10.3389/fped.2024.1285414
  title: 'Morquio B disease: a case report'
  found_in:
  - Morquio_syndrome-deep-research-falcon.md
  findings:
  - statement: 'Morquio B disease: a case report'
    supporting_text: Mucopolysaccharidosis IV type B, or Morquio B disease (MBD), is an autosomal recessive disorder caused by a genetic mutation in GLB1 gene encoding for β-galactosidase on chromosome 3p22.33. β-galactosidase deficiency can result in two different conditions, GM1 gangliosidosis and MBD, of which MBD has a milder phenotype and presents later in life with keratan sulfate accumulation in the retina and cartilage.
    evidence:
    - reference: DOI:10.3389/fped.2024.1285414
      reference_title: 'Morquio B disease: a case report'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Mucopolysaccharidosis IV type B, or Morquio B disease (MBD), is an autosomal recessive disorder caused by a genetic mutation in GLB1 gene encoding for β-galactosidase on chromosome 3p22.33. β-galactosidase deficiency can result in two different conditions, GM1 gangliosidosis and MBD, of which MBD has a milder phenotype and presents later in life with keratan sulfate accumulation in the retina and cartilage.
      explanation: Deep research cited this publication as relevant literature for Morquio syndrome.
- reference: DOI:10.3390/ijms21041517
  title: 'Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management'
  found_in:
  - Morquio_syndrome-deep-research-falcon.md
  findings:
  - statement: Mucopolysaccharidosis type IVA (MPS IVA, or Morquio syndrome type A) is an inherited metabolic lysosomal disease caused by the deficiency of the N-acetylglucosamine-6-sulfate sulfatase enzyme.
    supporting_text: Mucopolysaccharidosis type IVA (MPS IVA, or Morquio syndrome type A) is an inherited metabolic lysosomal disease caused by the deficiency of the N-acetylglucosamine-6-sulfate sulfatase enzyme.
    evidence:
    - reference: DOI:10.3390/ijms21041517
      reference_title: 'Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Mucopolysaccharidosis type IVA (MPS IVA, or Morquio syndrome type A) is an inherited metabolic lysosomal disease caused by the deficiency of the N-acetylglucosamine-6-sulfate sulfatase enzyme.
      explanation: Deep research cited this publication as relevant literature for Morquio syndrome.
- reference: DOI:10.3390/ijms25021113
  title: Molecular Mechanisms in Pathophysiology of Mucopolysaccharidosis and Prospects for Innovative Therapy
  found_in:
  - Morquio_syndrome-deep-research-falcon.md
  findings:
  - statement: Mucopolysaccharidoses (MPSs) are a group of inborn errors of the metabolism caused by a deficiency in the lysosomal enzymes required to break down molecules called glycosaminoglycans (GAGs).
    supporting_text: Mucopolysaccharidoses (MPSs) are a group of inborn errors of the metabolism caused by a deficiency in the lysosomal enzymes required to break down molecules called glycosaminoglycans (GAGs).
    evidence:
    - reference: DOI:10.3390/ijms25021113
      reference_title: Molecular Mechanisms in Pathophysiology of Mucopolysaccharidosis and Prospects for Innovative Therapy
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Mucopolysaccharidoses (MPSs) are a group of inborn errors of the metabolism caused by a deficiency in the lysosomal enzymes required to break down molecules called glycosaminoglycans (GAGs).
      explanation: Deep research cited this publication as relevant literature for Morquio syndrome.
- reference: PMID:35046639
  title: Clinical Utility of Elosulfase Alfa in the Treatment of Morquio A Syndrome.
  found_in:
  - Morquio_syndrome-deep-research-falcon.md
  findings:
  - statement: '2022 Jan 10;16:143-154. doi: 10.2147/DDDT.S219433. eCollection 2022.'
    supporting_text: '2022 Jan 10;16:143-154. doi: 10.2147/DDDT.S219433. eCollection 2022.'
    evidence:
    - reference: PMID:35046639
      reference_title: Clinical Utility of Elosulfase Alfa in the Treatment of Morquio A Syndrome.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2022 Jan 10;16:143-154. doi: 10.2147/DDDT.S219433. eCollection 2022.'
      explanation: Deep research cited this publication as relevant literature for Morquio syndrome.
📚

References & Deep Research

References

13
DOI:10.1016/j.omtm.2024.101313
A GLB1 transgene with enhanced therapeutic potential for the preclinical development of ex-vivo gene therapy to treat mucopolysaccharidosis type IVB
1 finding
A GLB1 transgene with enhanced therapeutic potential for the preclinical development of ex-vivo gene therapy to treat mucopolysaccharidosis type IVB
"A GLB1 transgene with enhanced therapeutic potential for the preclinical development of ex-vivo gene therapy to treat mucopolysaccharidosis type IVB"
Show evidence (1 reference)
PMID:39282079 SUPPORT Model Organism
"These results support the use of LV-enhGLB1 for further HSPC-GT development and future clinical translation to treat MPSIVB multisystem disease."
Preclinical HSPC gene therapy study in which LV-enhGLB1-transduced human HSPCs were validated in vivo (mouse transplantation), supporting an enhanced GLB1 transgene as a candidate ex-vivo gene therapy for MPS IVB.
DOI:10.1016/j.omtn.2024.102211
Adeno-associated virus-based gene therapy delivering combinations of two growth-associated genes to MPS IVA mice
1 finding
Adeno-associated virus-based gene therapy delivering combinations of two growth-associated genes to MPS IVA mice
"Adeno-associated virus-based gene therapy delivering combinations of two growth-associated genes to MPS IVA mice"
Show evidence (1 reference)
PMID:38831899 SUPPORT Model Organism
"Delivering combinations of CNP and GALNS gene therapies enhanced bone growth in MPS IVA mice more than in GALNS gene therapy alone."
MPS IVA mouse model study supporting AAV combination gene therapy (GALNS + CNP) for enhanced bone growth versus GALNS gene therapy alone.
DOI:10.1186/s13023-019-1074-9
Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance
1 finding
Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance
"Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance"
Show evidence (1 reference)
PMID:31196221 SUPPORT Other
"This manuscript provides evidence- and consensus-based recommendations for the management of patients with MPS IVA and is for use by healthcare professionals that manage the holistic care of patients with the intention to improve clinical- and patient-reported outcomes and enhance patient..."
International expert consensus and evidence-based recommendations for the management of patients with MPS IVA.
DOI:10.1186/s13023-021-01675-x
Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type IVA: results from a Managed Access Agreement in England
1 finding
Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type IVA: results from a Managed Access Agreement in England
"We present baseline characteristics and follow-up data of a Managed Access Agreement (MAA), including patients with mucopolysaccharidosis IVA (MPS IVA) receiving elosulfase alfa enzyme replacement therapy (ERT) in England on a conditional basis."
Show evidence (1 reference)
DOI:10.1186/s13023-021-01675-x SUPPORT Human Clinical
"We present baseline characteristics and follow-up data of a Managed Access Agreement (MAA), including patients with mucopolysaccharidosis IVA (MPS IVA) receiving elosulfase alfa enzyme replacement therapy (ERT) in England on a conditional basis."
Deep research cited this publication as relevant literature for Morquio syndrome.
DOI:10.1186/s13023-021-02074-y
Clinical features and health-related quality of life in adult patients with mucopolysaccharidosis IVA: the Spanish experience
1 finding
Mucopolysaccharidosis (MPS) IVA or Morquio A syndrome is a progressive and disabling disease characterized by a deficiency of the enzyme N-acetylgalactosamine-6-sulphate sulphatase.
"Mucopolysaccharidosis (MPS) IVA or Morquio A syndrome is a progressive and disabling disease characterized by a deficiency of the enzyme N-acetylgalactosamine-6-sulphate sulphatase."
Show evidence (1 reference)
DOI:10.1186/s13023-021-02074-y SUPPORT Human Clinical
"Mucopolysaccharidosis (MPS) IVA or Morquio A syndrome is a progressive and disabling disease characterized by a deficiency of the enzyme N-acetylgalactosamine-6-sulphate sulphatase."
Deep research cited this publication as relevant literature for Morquio syndrome.
DOI:10.1186/s13023-022-02332-7
Consensus statement on enzyme replacement therapy for mucopolysaccharidosis IVA in Central and South-Eastern European countries
1 finding
Mucopolysaccharidosis IVA (MPS IVA), or Morquio A syndrome, is a rare inherited metabolic disorder caused by deficiency of the lysosomal enzyme N-acetylgalactosamine-6-sulfatase.
"Mucopolysaccharidosis IVA (MPS IVA), or Morquio A syndrome, is a rare inherited metabolic disorder caused by deficiency of the lysosomal enzyme N-acetylgalactosamine-6-sulfatase."
Show evidence (1 reference)
DOI:10.1186/s13023-022-02332-7 SUPPORT Other
"Mucopolysaccharidosis IVA (MPS IVA), or Morquio A syndrome, is a rare inherited metabolic disorder caused by deficiency of the lysosomal enzyme N-acetylgalactosamine-6-sulfatase."
Deep research cited this publication as relevant literature for Morquio syndrome.
DOI:10.1186/s13023-024-03237-3
Consensus-based expert recommendations on the management of MPS IVa and VI in Saudi Arabia
1 finding
Consensus-based expert recommendations on the management of MPS IVa and VI in Saudi Arabia
"Mucopolysaccharidosis type IVa (Morquio A syndrome) and mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome) are rare inherited lysosomal storage diseases associated with significant functional impairment and a wide spectrum of debilitating clinical manifestations."
Show evidence (1 reference)
DOI:10.1186/s13023-024-03237-3 SUPPORT Other
"Mucopolysaccharidosis type IVa (Morquio A syndrome) and mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome) are rare inherited lysosomal storage diseases associated with significant functional impairment and a wide spectrum of debilitating clinical manifestations."
Deep research cited this publication as relevant literature for Morquio syndrome.
DOI:10.1186/s13023-024-03253-3
Novel approach for tracheal resection in Morquio a syndrome with end-stage critical airway obstruction: a UK case series
1 finding
Mucopolysaccharidosis (MPS) type IVA is a rare lysosomal storage disorder caused by aberrations of the N-acetyl-galactosamine-6-sulfatase (GALNS) enzyme.
"Mucopolysaccharidosis (MPS) type IVA is a rare lysosomal storage disorder caused by aberrations of the N-acetyl-galactosamine-6-sulfatase (GALNS) enzyme."
Show evidence (1 reference)
DOI:10.1186/s13023-024-03253-3 SUPPORT Human Clinical
"Mucopolysaccharidosis (MPS) type IVA is a rare lysosomal storage disorder caused by aberrations of the N-acetyl-galactosamine-6-sulfatase (GALNS) enzyme."
Deep research cited this publication as relevant literature for Morquio syndrome.
DOI:10.3389/fgene.2024.1343094
Identification of new variants in patients with mucopolysaccharidosis in consanguineous Iranian families
1 finding
Mucopolysaccharidoses are a group of lysosomal storage disorders that include seven types that are classified based on the enzymes that are disrupted.
"Mucopolysaccharidoses are a group of lysosomal storage disorders that include seven types that are classified based on the enzymes that are disrupted."
Show evidence (1 reference)
DOI:10.3389/fgene.2024.1343094 SUPPORT Human Clinical
"Mucopolysaccharidoses are a group of lysosomal storage disorders that include seven types that are classified based on the enzymes that are disrupted."
Deep research cited this publication as relevant literature for Morquio syndrome.
DOI:10.3389/fped.2024.1285414
Morquio B disease: a case report
1 finding
Morquio B disease: a case report
"Mucopolysaccharidosis IV type B, or Morquio B disease (MBD), is an autosomal recessive disorder caused by a genetic mutation in GLB1 gene encoding for β-galactosidase on chromosome 3p22.33. β-galactosidase deficiency can result in two different conditions, GM1 gangliosidosis and MBD, of which..."
Show evidence (1 reference)
DOI:10.3389/fped.2024.1285414 SUPPORT Human Clinical
"Mucopolysaccharidosis IV type B, or Morquio B disease (MBD), is an autosomal recessive disorder caused by a genetic mutation in GLB1 gene encoding for β-galactosidase on chromosome 3p22.33. β-galactosidase deficiency can result in two different conditions, GM1 gangliosidosis and MBD, of which..."
Deep research cited this publication as relevant literature for Morquio syndrome.
DOI:10.3390/ijms21041517
Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management
1 finding
Mucopolysaccharidosis type IVA (MPS IVA, or Morquio syndrome type A) is an inherited metabolic lysosomal disease caused by the deficiency of the N-acetylglucosamine-6-sulfate sulfatase enzyme.
"Mucopolysaccharidosis type IVA (MPS IVA, or Morquio syndrome type A) is an inherited metabolic lysosomal disease caused by the deficiency of the N-acetylglucosamine-6-sulfate sulfatase enzyme."
Show evidence (1 reference)
DOI:10.3390/ijms21041517 SUPPORT Human Clinical
"Mucopolysaccharidosis type IVA (MPS IVA, or Morquio syndrome type A) is an inherited metabolic lysosomal disease caused by the deficiency of the N-acetylglucosamine-6-sulfate sulfatase enzyme."
Deep research cited this publication as relevant literature for Morquio syndrome.
DOI:10.3390/ijms25021113
Molecular Mechanisms in Pathophysiology of Mucopolysaccharidosis and Prospects for Innovative Therapy
1 finding
Mucopolysaccharidoses (MPSs) are a group of inborn errors of the metabolism caused by a deficiency in the lysosomal enzymes required to break down molecules called glycosaminoglycans (GAGs).
"Mucopolysaccharidoses (MPSs) are a group of inborn errors of the metabolism caused by a deficiency in the lysosomal enzymes required to break down molecules called glycosaminoglycans (GAGs)."
Show evidence (1 reference)
DOI:10.3390/ijms25021113 SUPPORT Human Clinical
"Mucopolysaccharidoses (MPSs) are a group of inborn errors of the metabolism caused by a deficiency in the lysosomal enzymes required to break down molecules called glycosaminoglycans (GAGs)."
Deep research cited this publication as relevant literature for Morquio syndrome.
PMID:35046639
Clinical Utility of Elosulfase Alfa in the Treatment of Morquio A Syndrome.
1 finding
2022 Jan 10;16:143-154. doi: 10.2147/DDDT.S219433. eCollection 2022.
"2022 Jan 10;16:143-154. doi: 10.2147/DDDT.S219433. eCollection 2022."
Show evidence (1 reference)
PMID:35046639 SUPPORT Other
"2022 Jan 10;16:143-154. doi: 10.2147/DDDT.S219433. eCollection 2022."
Deep research cited this publication as relevant literature for Morquio syndrome.

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 41 citations 2026-05-10T05:44:04.819341

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Morquio syndrome
  • MONDO ID: (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Morquio syndrome covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Research Report: Morquio syndrome (Mucopolysaccharidosis type IV)

Scope and evidence note

This report synthesizes evidence retrieved via the toolchain (peer‑reviewed articles and ClinicalTrials.gov records). Direct access to OMIM/Orphanet/MeSH/MONDO pages was not available in the retrieved full texts; therefore, several standard identifiers (OMIM disease numbers, Orphanet IDs, MeSH terms, ICD‑10/ICD‑11 codes, MONDO IDs) could not be verified from primary source pages within this run and are explicitly marked as not available in retrieved evidence.

A structured summary table suitable for knowledge‑base ingestion is provided below.

Topic MPS IVA (Morquio A) MPS IVB (Morquio B) Key citations
Subtype / definition Major Morquio syndrome subtype; lysosomal storage disease with predominant skeletal dysplasia and generally normal intellect Rarer Morquio subtype; GLB1-related skeletal dysplasia phenotype distinct from GM1 gangliosidosis, usually milder/later-presenting and generally normal intellect (lee2022clinicalutilityof pages 1-2, sawamoto2020mucopolysaccharidosisivadiagnosis pages 1-3, crippa2024aglb1transgene pages 1-2, gholamian2024morquiobdisease pages 1-2)
Causal gene GALNS GLB1 (lee2022clinicalutilityof pages 1-2, sawamoto2020mucopolysaccharidosisivadiagnosis pages 1-3, crippa2024aglb1transgene pages 1-2, gholamian2024morquiobdisease pages 1-2)
Deficient enzyme N-acetylgalactosamine-6-sulfatase (GALNS; EC 3.1.6.4) β-galactosidase (β-GAL) (lee2022clinicalutilityof pages 1-2, sawamoto2020mucopolysaccharidosisivadiagnosis pages 1-3, crippa2024aglb1transgene pages 1-2, gholamian2024morquiobdisease pages 1-2)
Stored substrates Keratan sulfate (KS) and chondroitin-6-sulfate (C6S) accumulate, especially in bone/cartilage/ECM Keratan sulfate accumulates, especially in cartilage and retina (lee2022clinicalutilityof pages 1-2, sawamoto2020mucopolysaccharidosisivadiagnosis pages 1-3, crippa2024aglb1transgene pages 1-2, gholamian2024morquiobdisease pages 1-2)
Inheritance Autosomal recessive Autosomal recessive (lee2022clinicalutilityof pages 1-2, sawamoto2020mucopolysaccharidosisivadiagnosis pages 1-3, gholamian2024morquiobdisease pages 1-2)
Key clinical features Disproportionate short stature, skeletal dysplasia, platyspondyly, kyphoscoliosis, genu valgum, joint laxity, pectus carinatum, odontoid/cervical instability, tracheal obstruction, corneal clouding, hearing loss; adults often have pain, mobility loss, self-care dependence Dysostosis multiplex/Morquio dysostosis, disproportionate short stature, atlantoaxial instability, odontoid hypoplasia, platyspondyly, kyphoscoliosis, coxa valga/genu valgum, joint laxity, corneal clouding, hearing loss, dental/cardiopulmonary issues (quijadafraile2021clinicalfeaturesand pages 1-2, sawamoto2020mucopolysaccharidosisivadiagnosis pages 1-3, crippa2024aglb1transgene pages 1-2, gholamian2024morquiobdisease pages 1-2)
Key biomarkers / diagnostics Low GALNS activity in leukocytes/fibroblasts or DBS; molecular confirmation; urinary KS/uGAGs useful but age-dependent; radiographs and multisystem assessment essential; LC-MS/MS supports multiplex/newborn screening workflows Low leukocyte β-galactosidase activity; GLB1 sequencing; urinary mucopolysaccharides/oligosaccharide abnormalities may support diagnosis; characteristic radiography (lee2022clinicalutilityof pages 1-2, sawamoto2020mucopolysaccharidosisivadiagnosis pages 1-3, alsayed2024consensusbasedexpertrecommendations pages 5-6, sawamoto2020mucopolysaccharidosisivadiagnosis pages 20-22, gholamian2024morquiobdisease pages 1-2)
Approved disease-modifying therapy Elosulfase alfa IV ERT (2 mg/kg weekly) is approved/standard disease-specific therapy; improves or stabilizes endurance, respiratory outcomes, uKS, and some PROs, but limited effect on bone, eyes, and some airway/cardiac disease No approved disease-modifying therapy identified in retrieved evidence (cleary2021impactoflongterm pages 1-2, NCT00884949 chunk 1, magner2022consensusstatementon pages 1-2, crippa2024aglb1transgene pages 1-2)
HSCT status Available in some centers historically, but evidence/guidelines indicate limited skeletal benefit and 2024 Saudi consensus states HSCT is ineffective for MPS IVA No established role identified in retrieved evidence (sawamoto2020mucopolysaccharidosisivadiagnosis pages 1-3, alsayed2024consensusbasedexpertrecommendations pages 6-8)
Notable recent (2024) developments 2024 Saudi consensus: early diagnosis, immediate treatment after counseling, multidisciplinary centers, DBS/LC-MS/MS, pilot newborn screening, home-infusion programs; 2024 AAV9/AAV8 combination gene therapy study in MPS IVA mice delivering GALNS plus CNP for skeletal benefit; 2024 UK case series showed transcervical tracheal resection with partial manubriectomy improved spirometry/QoL in severe airway disease 2024 preclinical ex vivo HSPC gene therapy work developed an enhanced GLB1 lentiviral construct with improved enzyme release/cross-correction; 2024 case report detailed orthopedic progression/management in adolescent MPS IVB (alsayed2024consensusbasedexpertrecommendations pages 5-6, alsayed2024consensusbasedexpertrecommendations pages 6-8, kenth2024novelapproachfor pages 9-12, kenth2024novelapproachfor pages 1-2, kenth2024novelapproachfor pages 12-13, rintz2024adenoassociatedvirusbasedgene pages 1-2, crippa2024aglb1transgene pages 1-2, crippa2024aglb1transgene pages 14-16, gholamian2024morquiobdisease pages 1-2)
Key real-world implementations England Managed Access Agreement: 55 patients, conditional access with annual review; mean 6MWT rose from 217 m to 244 m after ~4.9 years, FVC/FEV1 from 0.87/0.78 L to 1.05/0.88 L after ~5.5 years; UK specialist airway surgery pathway with AAA 3D planning and MDT selection; regional consensus statements in Europe/Saudi Arabia emphasize multidisciplinary centers and reimbursement/access frameworks No approved therapy implementation pathway identified; current real-world care is largely symptomatic/orthopedic and multidisciplinary (cleary2021impactoflongterm pages 1-2, magner2022consensusstatementon pages 1-2, kenth2024novelapproachfor pages 9-12, kenth2024novelapproachfor pages 1-2, kenth2024novelapproachfor pages 4-6, alsayed2024consensusbasedexpertrecommendations pages 5-6, alsayed2024consensusbasedexpertrecommendations pages 6-8)
Epidemiology / prevalence notes Birth prevalence reported variably by country, e.g., Denmark 1/323,000; UK 1/599,000; Australia 1/926,000; Malaysia 1/1,872,000; broader review range ~1:76,000 to 1:640,000 births Reported prevalence about 1 in 250,000; incidence estimates ~1/250,000–1,000,000 births (lee2022clinicalutilityof pages 1-2, sawamoto2020mucopolysaccharidosisivadiagnosis pages 1-3, crippa2024aglb1transgene pages 1-2, gholamian2024morquiobdisease pages 1-2)

Table: This table condenses the most actionable structured facts about Morquio syndrome (MPS IV) for knowledge-base ingestion, separating MPS IVA and MPS IVB while highlighting diagnostics, therapy, epidemiology, and 2024 developments. It is designed to support rapid curation with direct context-ID citations.

1. Disease information

1.1 What is Morquio syndrome?

Morquio syndrome is a lysosomal storage disorder within the mucopolysaccharidoses (MPS) characterized by defective degradation of glycosaminoglycans (GAGs) and prominent skeletal dysplasia. The term commonly encompasses MPS IVA (Morquio A) and MPS IVB (Morquio B), which are genetically distinct entities with overlapping skeletal phenotypes. Morquio A is caused by deficiency of N‑acetylgalactosamine‑6‑sulfatase (GALNS) leading to keratan sulfate (KS) and chondroitin‑6‑sulfate (C6S) storage, while Morquio B is caused by β‑galactosidase deficiency due to GLB1 variants, leading to KS storage (particularly in cartilage and retina). (lee2022clinicalutilityof pages 1-2, sawamoto2020mucopolysaccharidosisivadiagnosis pages 1-3, crippa2024aglb1transgene pages 1-2, gholamian2024morquiobdisease pages 1-2)

1.2 Key identifiers (availability in retrieved evidence)

  • OMIM (disease/gene IDs): Not available in the retrieved evidence for MPS IVA/IVB; one 2024 genetics paper included OMIM IDs for other MPS types but not MPS IV. (zabihi2024identificationofnew pages 1-2)
  • Orphanet ID: Not available in retrieved evidence.
  • ICD‑10/ICD‑11: Not available in retrieved evidence.
  • MeSH: ClinicalTrials.gov records include MeSH condition term “Mucopolysaccharidosis IV” for elosulfase alfa trials/long‑term studies. (NCT01242111 chunk 2)
  • MONDO: Not available in retrieved evidence.

1.3 Synonyms and alternative names

  • Morquio syndrome
  • Morquio A syndrome; MPS IVA; “Morquio–Brailsford” (Morquio A) (lee2022clinicalutilityof pages 1-2)
  • Morquio B disease; MPS IVB (gholamian2024morquiobdisease pages 1-2)

1.4 Evidence source type

The information is derived primarily from aggregated disease‑level resources (consensus guidelines/reviews and cohorts) and clinical trial/real‑world datasets, with additional evidence from case reports and preclinical model studies. (cleary2021impactoflongterm pages 1-2, alsayed2024consensusbasedexpertrecommendations pages 5-6, kenth2024novelapproachfor pages 9-12, gholamian2024morquiobdisease pages 1-2, rintz2024adenoassociatedvirusbasedgene pages 1-2, crippa2024aglb1transgene pages 1-2)

2. Etiology

2.1 Disease causal factors

Genetic/biochemical cause (Mendelian): - MPS IVA (Morquio A): autosomal recessive lysosomal enzyme deficiency of GALNS causing impaired degradation of KS and C6S. (lee2022clinicalutilityof pages 1-2, sawamoto2020mucopolysaccharidosisivadiagnosis pages 1-3) - MPS IVB (Morquio B): autosomal recessive GLB1 mutations causing β‑galactosidase deficiency and KS accumulation; GLB1 deficiency can also cause GM1 gangliosidosis, while Morquio B represents a primarily skeletal/retinal phenotype. (gholamian2024morquiobdisease pages 1-2, crippa2024aglb1transgene pages 1-2)

2.2 Risk factors

  • Carrier status and family history in an autosomal recessive disorder; no environmental triggers are required.
  • Consanguinity is highlighted by Saudi experts as a driver of higher local prevalence for MPS IVa and VI in Saudi Arabia. (alsayed2024consensusbasedexpertrecommendations pages 2-4)

2.3 Protective factors

No validated genetic “protective variants” or environmental protective factors were identified in the retrieved evidence.

2.4 Gene–environment interactions

No specific gene–environment interaction evidence was identified in the retrieved corpus.

3. Phenotypes

3.1 Core phenotype spectrum (MPS IVA emphasized)

Morquio A exhibits a phenotypic continuum (classical to non‑classical). In an adult Spanish cohort (n=33), phenotypes were 54.5% classical, 33.3% intermediate, and 12.1% non‑classical. (quijadafraile2021clinicalfeaturesand pages 1-2)

Key manifestations in this adult cohort (frequencies): - Hearing loss: 75.7% (quijadafraile2021clinicalfeaturesand pages 1-2) - Ligamentous laxity: 72.7% (quijadafraile2021clinicalfeaturesand pages 1-2) - Odontoid dysplasia: 69.7% (quijadafraile2021clinicalfeaturesand pages 1-2) - Limb deformities requiring orthopaedic aids (e.g., hip dysplasia, genu valgum): 63.6% (quijadafraile2021clinicalfeaturesand pages 1-2) - Corneal clouding: 60.6% (quijadafraile2021clinicalfeaturesand pages 1-2) - Obstructive sleep apnea/hypopnea syndrome (OSAHS): 36.0% (quijadafraile2021clinicalfeaturesand pages 1-2) - Need for non‑invasive ventilation: 33.3% (quijadafraile2021clinicalfeaturesand pages 1-2)

Functional/quality‑of‑life impact in adults: - ~80% had mobility problems; 36.4% used a wheelchair at all times; 87.9% needed help with self‑care; 33.3% were fully dependent; 78.8% had pain. (quijadafraile2021clinicalfeaturesand pages 1-2)

Morquio A skeletal phenotype and clinical suspicion often arise from radiographic skeletal dysplasia in the preschool years, with progressive multisystem involvement. (lee2022clinicalutilityof pages 1-2, sawamoto2020mucopolysaccharidosisivadiagnosis pages 1-3)

3.2 Morquio B (MPS IVB) phenotypes

Morquio B is typically milder and later‑presenting than GM1 gangliosidosis, with generally normal cognition. In a 2024 case report, classic “Morquio dysostosis multiplex” radiographic findings were present, with progressive deterioration of walking in adolescence due to joint instability and pain; biochemical testing showed reduced leukocyte β‑galactosidase activity (12.3 nmol/h/mg protein) and elevated urinary mucopolysaccharides (18 mg/mmol). (gholamian2024morquiobdisease pages 1-2)

3.3 Suggested HPO terms (non‑exhaustive; mapped to phenotypes in retrieved evidence)

  • Short stature, disproportionate (HP:0003510)
  • Kyphoscoliosis (HP:0008453)
  • Genu valgum (HP:0002857)
  • Hip dysplasia (HP:0001385)
  • Joint laxity (HP:0001382)
  • Odontoid hypoplasia/dysplasia (HP:0011817)
  • Cervical spinal stenosis / spinal cord compression (HP:0003416)
  • Pectus carinatum (HP:0000768)
  • Corneal clouding (HP:0007957)
  • Hearing impairment (HP:0000365)
  • Obstructive sleep apnea (HP:0010535)
  • Pain (HP:0012531)

3.4 Anatomy affected (high‑level)

Primary involvement: skeletal system (spine, hips, long bones, growth plates), airway (trachea), and connective tissues; secondary involvement includes cardiopulmonary and ENT systems. (quijadafraile2021clinicalfeaturesand pages 1-2, sawamoto2020mucopolysaccharidosisivadiagnosis pages 1-3, kenth2024novelapproachfor pages 1-2)

Suggested UBERON examples: growth plate cartilage (UBERON:0001988), trachea (UBERON:0003126), vertebral column (UBERON:0001130), cornea (UBERON:0000964).

4. Genetic / molecular information

4.1 Causal genes

  • GALNS → MPS IVA (Morquio A) (lee2022clinicalutilityof pages 1-2, sawamoto2020mucopolysaccharidosisivadiagnosis pages 1-3)
  • GLB1 → MPS IVB (Morquio B) (crippa2024aglb1transgene pages 1-2, gholamian2024morquiobdisease pages 1-2)

4.2 Pathogenic variants and variant classes

MPS IVA (GALNS): broad allelic heterogeneity; one 2022 review reports ClinVar counts (as of Aug 2021) and notes numerous pathogenic/likely pathogenic variants. (lee2022clinicalutilityof pages 1-2)

MPS IVB (GLB1): recurrent variants associated with Morquio B skeletal phenotypes include p.Tyr83His, p.Thr500Ala, p.Trp273Leu, and a case report described a compound genotype W273L/N484K. (crippa2024aglb1transgene pages 1-2, gholamian2024morquiobdisease pages 1-2)

4.3 Functional consequences

Both subtypes are consistent with loss‑of‑function enzyme deficiency, leading to lysosomal accumulation of incompletely degraded substrates (KS ± C6S). (lee2022clinicalutilityof pages 1-2, crippa2024aglb1transgene pages 1-2)

4.4 Modifier/protective genes and epigenetics

No validated modifier genes, protective alleles, or epigenetic signatures specific to Morquio syndrome were identified in the retrieved evidence.

5. Environmental information

Morquio syndrome is a genetic lysosomal storage disorder; no environmental causes were identified. Population‑level factors such as consanguinity influence observed prevalence in some regions. (alsayed2024consensusbasedexpertrecommendations pages 2-4)

6. Mechanism / pathophysiology

6.1 Causal chain (current understanding)

A 2024 mechanistic synthesis of mucopolysaccharidoses describes a general cascade: 1) Primary storage: lysosomal enzyme deficiency → progressive GAG accumulation. 2) Organelle dysfunction: disruption of lysosomal function, impaired autophagy, and mitochondrial dysfunction. 3) Downstream stress and inflammation: increased oxidative stress and activation of innate immunity/inflammation. 4) Tissue damage: progressive organ damage and cell death manifesting as skeletal dysplasia and (in many MPS types) CNS impairment. (ago2024molecularmechanismsin pages 1-2)

For Morquio (MPS IV), the stored substrates (KS/C6S) preferentially affect cartilage and growth plates, contributing to a distinct skeletal dysplasia pattern (e.g., platyspondyly and anterior beaking). (ago2024molecularmechanismsin pages 7-9)

6.2 Key pathways and processes (suggested GO terms)

Based on 2024 synthesis, relevant processes include: - Lysosome organization/function (GO:0007040) - Autophagy / mitophagy (GO:0006914; GO:0000422) - Oxidative stress response (GO:0006979) - Innate immune response / NF‑κB signaling (GO:0045087; GO:0043122) - Inflammasome complex activation (GO:1902552) (ago2024molecularmechanismsin pages 1-2, ago2024molecularmechanismsin pages 11-14, ago2024molecularmechanismsin pages 7-9)

6.3 Cell types (suggested CL terms)

  • Chondrocyte (CL:0000138)
  • Osteoblast (CL:0000062)
  • Osteoclast (CL:0000092)
  • Macrophage / microglia (CL:0000235; CL:0000129) (ago2024molecularmechanismsin pages 2-3, crippa2024aglb1transgene pages 14-16)

6.4 Implications for therapeutic delivery

The 2024 review emphasizes that conventional IV ERT has limited impact on bone/cartilage and does not address BBB‑restricted compartments, motivating approaches such as receptor‑mediated transcytosis (“molecular Trojan horses”) for CNS delivery and bone‑targeting strategies. (ago2024molecularmechanismsin pages 11-14, ago2024molecularmechanismsin pages 2-3)

7. Anatomical structures affected

  • Skeletal system: vertebrae, growth plates, hips, long bones; cervical spine/odontoid region. (quijadafraile2021clinicalfeaturesand pages 1-2, sawamoto2020mucopolysaccharidosisivadiagnosis pages 1-3)
  • Respiratory/airway: trachea with multilevel pathology (tracheomalacia, stenosis, tortuosity/buckling). (kenth2024novelapproachfor pages 1-2)
  • Eye: corneal clouding. (quijadafraile2021clinicalfeaturesand pages 1-2)
  • Ear/ENT: hearing loss. (quijadafraile2021clinicalfeaturesand pages 1-2)

Subcellular: lysosome (GO:0005764) as primary site of storage pathology (ago2024molecularmechanismsin pages 1-2).

8. Temporal development

8.1 Onset

Neonates may appear normal; disease is often suspected in early childhood when skeletal abnormalities and radiographic dysplasia become apparent. Attenuated forms can present later and survive into adulthood. (sawamoto2020mucopolysaccharidosisivadiagnosis pages 1-3)

8.2 Progression

Progressive course with worsening skeletal deformity, mobility limitation, pain, and cardiopulmonary/airway complications. End‑stage airway obstruction can become life‑threatening in severe Morquio A. (quijadafraile2021clinicalfeaturesand pages 1-2, kenth2024novelapproachfor pages 1-2)

9. Inheritance and population

9.1 Inheritance

Autosomal recessive for both MPS IVA and MPS IVB. (lee2022clinicalutilityof pages 1-2, gholamian2024morquiobdisease pages 1-2)

9.2 Epidemiology

Reported birth prevalence for MPS IVA varies widely by country. A 2022 review provides examples: Denmark 1/323,000, UK 1/599,000, Australia 1/926,000, Malaysia 1/1,872,000. A 2020 review gives a broader prevalence range of ~1:76,000 to 1:640,000 births. (lee2022clinicalutilityof pages 1-2, sawamoto2020mucopolysaccharidosisivadiagnosis pages 1-3)

For MPS IVB, a 2024 gene‑therapy development paper cites prevalence ~1 in 250,000 and carrier frequency ~1 in 250, while a 2024 case report cites incidence estimates ~1/250,000–1,000,000 births. (crippa2024aglb1transgene pages 1-2, gholamian2024morquiobdisease pages 1-2)

9.3 Population considerations

Saudi experts highlight higher‑than‑average prevalence in Saudi Arabia attributed to high consanguinity rates, motivating registry and screening initiatives. (alsayed2024consensusbasedexpertrecommendations pages 2-4)

10. Diagnostics

10.1 Clinical and biochemical testing

MPS IVA: diagnosis generally requires demonstration of low GALNS activity (leukocytes/fibroblasts; DBS can be used as an initial/remote sample) plus molecular confirmation; urinary KS is a biomarker but declines with age so requires age‑appropriate interpretation. (lee2022clinicalutilityof pages 1-2, akyol2019recommendationsforthe pages 1-2)

MPS IVB: reduced leukocyte β‑galactosidase activity and GLB1 sequencing; supportive urinary testing may include elevated mucopolysaccharides and abnormal oligosaccharide electrophoresis. (gholamian2024morquiobdisease pages 1-2)

10.2 Biomarkers and advanced assays / screening

A 2024 Saudi consensus notes dried blood spot (DBS) assays and LC‑MS/MS as precise methods suitable for multiplex newborn screening; the panel recommends piloting newborn screening initiatives and improving access to molecular testing. (alsayed2024consensusbasedexpertrecommendations pages 5-6, alsayed2024consensusbasedexpertrecommendations pages 2-4)

A 2020 MPS IVA review describes LC‑MS/MS and other quantitative assays for KS and related biomarkers (including di‑sulfated KS and C6S) and discusses pilot newborn screening approaches. (sawamoto2020mucopolysaccharidosisivadiagnosis pages 20-22)

10.3 Imaging and functional testing

Radiographic skeletal dysplasia drives suspicion, and severe airway disease requires dedicated assessment. A 2024 UK surgical series used advanced CT‑based “Advanced Airway Analytics” with 3D reconstruction/virtual endoscopy to quantify narrowing and plan interventions. (kenth2024novelapproachfor pages 8-9)

10.4 Differential diagnosis

Not exhaustively retrievable within this run; in practice includes other skeletal dysplasias and other MPS subtypes with overlapping dysostosis multiplex.

11. Outcome / prognosis

11.1 Morbidity and function

Adult cohort data show substantial disability and pain burden (mobility impairment, wheelchair dependence, self‑care dependence) and reduced HRQoL, requiring multidisciplinary care. (quijadafraile2021clinicalfeaturesand pages 1-2)

11.2 Survival and mortality

Specific survival curves or life expectancy estimates were not retrieved in the available evidence set.

11.3 Real‑world outcomes with therapy (disease‑modifying and interventional)

Elosulfase alfa (ERT) in England managed access agreement (real‑world): - 55 patients; mean 6‑minute walk test increased from 217 m to 244 m after mean follow‑up 4.9 years. - Mean FVC/FEV1 improved from 0.87/0.78 L to 1.05/0.88 L after mean follow‑up 5.5 years. - Patient‑reported outcomes showed improvements in mobility/self‑care domains and relatively stable QoL. (cleary2021impactoflongterm pages 1-2)

Severe airway obstruction surgery (2024 UK case series): Seven adolescents underwent transcervical tracheal resection with partial manubriectomy, reporting spirometric improvement and QoL gains. Pre‑ and post‑operative spirometry values for each subject are summarized in Table 3 (image evidence). (kenth2024novelapproachfor pages 1-2, kenth2024novelapproachfor pages 12-13, kenth2024novelapproachfor media 9eafb273)

12. Treatment

12.1 Pharmacotherapy: enzyme replacement therapy (ERT)

Elosulfase alfa (recombinant GALNS) is the principal approved disease‑specific therapy for MPS IVA, administered IV (commonly 2 mg/kg weekly). Clinical reviews note improvements in endurance and respiratory outcomes versus placebo and reduction in urinary GAGs/KS. (lee2022clinicalutilityof pages 1-2, NCT00884949 chunk 1)

Limitations: 2024 Saudi experts emphasize ERT requires weekly costly infusions and has limited efficacy for ocular, skeletal, and some cardiac manifestations, supporting early initiation and improved care models. (alsayed2024consensusbasedexpertrecommendations pages 2-4)

Real‑world long‑term stabilization/improvement is supported by the England managed access dataset. (cleary2021impactoflongterm pages 1-2)

12.2 Surgical/interventional and supportive care

Airway disease can progress to life‑threatening obstruction. In 2024, a UK MDT implemented a transcervical tracheal resection approach avoiding cardiopulmonary bypass, demonstrating meaningful spirometric improvement and improved patient‑reported QoL (PedsQL domains). (kenth2024novelapproachfor pages 1-2, kenth2024novelapproachfor pages 12-13, kenth2024novelapproachfor media 9eafb273)

12.3 HSCT

A 2024 Saudi consensus states HSCT is ineffective for MPS IVa. Earlier reviews note HSCT availability but limited skeletal impact and significant risks. (alsayed2024consensusbasedexpertrecommendations pages 6-8, sawamoto2020mucopolysaccharidosisivadiagnosis pages 1-3)

12.4 Emerging / experimental therapies (prioritize 2023–2024)

MPS IVA—AAV gene therapy (preclinical; 2024): A 2024 Molecular Therapy – Nucleic Acids study tested systemic AAV delivery of GALNS together with a growth‑associated gene NPPC/CNP in MPS IVA mice. The rationale is that enzyme delivery alone may not sufficiently correct avascular growth‑plate cartilage; combining enzyme restoration with growth‑plate signaling may improve skeletal outcomes. The study reports increased GALNS activity in multiple tissues (including bone) and bone growth effects, but also highlights dose‑related adverse effects with high‑dose CNP. (rintz2024adenoassociatedvirusbasedgene pages 1-2)

MPS IVB—ex vivo HSPC gene therapy (preclinical; 2024): A 2024 Methods & Clinical Development paper developed an enhanced GLB1/β‑galactosidase approach for ex vivo lentiviral HSPC gene therapy, addressing instability/poor extracellular release of human β‑GAL. Supernatants from LV‑enhGLB1‑transduced myeloid cells/osteoclasts corrected patient fibroblasts, supporting further development. (crippa2024aglb1transgene pages 14-16)

Innovative delivery platforms (broader MPS; 2024 synthesis): A 2024 mechanistic review highlights receptor‑mediated BBB transport (“molecular Trojan horses”) and bone‑targeting enzyme strategies as key directions for MPS therapies, relevant to Morquio’s bone‑dominant pathology. (ago2024molecularmechanismsin pages 11-14, ago2024molecularmechanismsin pages 2-3)

12.5 Clinical trials (selected; ClinicalTrials.gov)

Key elosulfase alfa trials include: - Phase 1/2 study of BMN‑110 (elosulfase alfa): NCT00884949 (NCT00884949 chunk 1) - Long‑term efficacy/safety study: NCT01242111 (NCT01242111 chunk 2)

13. Prevention

Because Morquio syndrome is autosomal recessive, prevention focuses on genetic services and early detection rather than exposure modification.

Secondary prevention (early detection): Saudi experts recommend piloting newborn screening initiatives and improving DBS/LC‑MS/MS workflows, paired with confirmatory enzyme/molecular testing. (alsayed2024consensusbasedexpertrecommendations pages 5-6, alsayed2024consensusbasedexpertrecommendations pages 2-4)

Primary prevention (genetic counseling): The 2024 Saudi consensus recommends premarital screening and enhanced genetic counseling for families with known MPS history, reflecting population risk from consanguinity. (alsayed2024consensusbasedexpertrecommendations pages 5-6, alsayed2024consensusbasedexpertrecommendations pages 6-8)

14. Other species / natural disease

No evidence of naturally occurring Morquio syndrome in non‑human species (companion animals/wildlife) was retrieved in this run.

15. Model organisms

15.1 MPS IVA models

  • Mouse models: used for substrate‑degradation enzyme therapy and AAV gene transfer; reduction in circulating KS and improved bone pathology have been demonstrated in preclinical interventions. (sawamoto2020mucopolysaccharidosisivadiagnosis pages 11-13)
  • Cellular models: human MPS IVA fibroblasts and murine MPS IVA chondrocytes have been used to test AAV vectors and assess GALNS activity and chondrocyte pathology. (sawamoto2020mucopolysaccharidosisivadiagnosis pages 11-13)
  • AAV gene therapy in mice (2024): combination AAV‑GALNS and AAV‑NPPC/CNP to address skeletal growth plate pathology. (rintz2024adenoassociatedvirusbasedgene pages 1-2)

15.2 MPS IVB models

  • Ex vivo HSPC models, differentiated myeloid cells/osteoclasts/osteoblasts, and patient fibroblast cross‑correction assays; preliminary use of Glb1−/− mouse BM HSPCs for testing enhanced enzyme constructs. (crippa2024aglb1transgene pages 14-16)

Expert opinions and implementation analysis (2024)

A 2024 Saudi Delphi‑based consensus emphasizes implementation gaps and recommends: multidisciplinary centers of excellence, periodic training, national registries, improved access to enzyme and molecular testing, piloting newborn screening using LC‑MS/MS, and developing home‑infusion programs for ERT to improve adherence and reduce logistical barriers. (alsayed2024consensusbasedexpertrecommendations pages 5-6, alsayed2024consensusbasedexpertrecommendations pages 6-8, alsayed2024consensusbasedexpertrecommendations pages 2-4)

Required abstract quotes (direct excerpts)

  • 2024 mechanistic synthesis (MPS pathophysiology cascade): “At the initial stage of GAG accumulation, affected tissues/cells are reversibly affected but progress irreversibly to: (1) disruption of substrate degradation with pathogenic changes in lysosomal function, (2) cellular dysfunction, secondary/tertiary accumulation … and inflammatory process, and (3) progressive tissue/organ damage and cell death (e.g., skeletal dysplasia, CNS impairment, etc.).” (ago2024molecularmechanismsin pages 1-2)
  • 2024 Morquio B case report: “Mucopolysaccharidosis IV type B, or Morquio B disease (MBD), is an autosomal recessive disorder caused by a genetic mutation in GLB1 gene encoding for β-galactosidase…” (gholamian2024morquiobdisease pages 1-2)

URLs and publication dates (examples of key 2024 sources)

  • AlSayed et al. “Consensus-based expert recommendations on the management of MPS IVa and VI in Saudi Arabia.” Orphanet J Rare Dis. July 2024. https://doi.org/10.1186/s13023-024-03237-3 (alsayed2024consensusbasedexpertrecommendations pages 2-4)
  • Kenth et al. “Novel approach for tracheal resection in Morquio a syndrome…” Orphanet J Rare Dis. July 2024. https://doi.org/10.1186/s13023-024-03253-3 (kenth2024novelapproachfor pages 1-2)
  • Rintz et al. “Adeno-associated virus-based gene therapy…” Mol Ther Nucleic Acids. June 2024. https://doi.org/10.1016/j.omtn.2024.102211 (rintz2024adenoassociatedvirusbasedgene pages 1-2)
  • Crippa et al. “A GLB1 transgene with enhanced therapeutic potential…” Mol Ther Methods Clin Dev. September 2024. https://doi.org/10.1016/j.omtm.2024.101313 (crippa2024aglb1transgene pages 1-2)
  • Ago et al. “Molecular Mechanisms in Pathophysiology of Mucopolysaccharidosis…” IJMS. January 2024. https://doi.org/10.3390/ijms25021113 (ago2024molecularmechanismsin pages 1-2)

Evidence gaps (for knowledge base curation)

  • Standard identifiers (OMIM/Orphanet/ICD/MONDO) were not retrievable directly; they should be added from authoritative databases.
  • Survival/life expectancy statistics were not captured in the retrieved set.
  • Detailed newborn screening performance metrics (sensitivity/PPV) and long-term outcomes from NBS implementation were not available in retrieved evidence.
  • Naturally occurring animal disease evidence was not retrieved.

References

  1. (lee2022clinicalutilityof pages 1-2): Chung-Lin Lee, C. Chuang, Huei-Ching Chiu, Ru-Yi Tu, Yun-Ting Lo, Ya-Hui Chang, Shuan-Pei Lin, and Hsiang-Yu Lin. Clinical utility of elosulfase alfa in the treatment of morquio a syndrome. Drug Design, Development and Therapy, 16:143-154, Jan 2022. URL: https://doi.org/10.2147/dddt.s219433, doi:10.2147/dddt.s219433. This article has 16 citations.

  2. (sawamoto2020mucopolysaccharidosisivadiagnosis pages 1-3): Kazuki Sawamoto, José Álvarez González, Matthew Piechnik, Francisco Otero, Maria Couce, Yasuyuki Suzuki, and Shunji Tomatsu. Mucopolysaccharidosis iva: diagnosis, treatment, and management. International Journal of Molecular Sciences, 21:1517, Feb 2020. URL: https://doi.org/10.3390/ijms21041517, doi:10.3390/ijms21041517. This article has 160 citations.

  3. (crippa2024aglb1transgene pages 1-2): Stefania Crippa, Gaia Alberti, Laura Passerini, Evelyn Oliva Savoia, Marilena Mancino, Giada De Ponti, Ludovica Santi, Margherita Berti, Marialuisa Testa, Raisa Jofra Hernandez, Pamela Quaranta, Selene Ceriotti, Ilaria Visigalli, Amelia Morrone, Antonella Paoli, Claudia Forni, Serena Scala, Massimo Degano, Leopoldo Staiano, Silvia Gregori, Alessandro Aiuti, and Maria Ester Bernardo. A glb1 transgene with enhanced therapeutic potential for the preclinical development of ex-vivo gene therapy to treat mucopolysaccharidosis type ivb. Molecular Therapy - Methods & Clinical Development, 32:101313, Sep 2024. URL: https://doi.org/10.1016/j.omtm.2024.101313, doi:10.1016/j.omtm.2024.101313. This article has 4 citations.

  4. (gholamian2024morquiobdisease pages 1-2): Tara Gholamian, Harpreet Chhina, Sylvia Stockler, and Anthony Cooper. Morquio b disease: a case report. Frontiers in Pediatrics, Mar 2024. URL: https://doi.org/10.3389/fped.2024.1285414, doi:10.3389/fped.2024.1285414. This article has 3 citations.

  5. (quijadafraile2021clinicalfeaturesand pages 1-2): Pilar Quijada-Fraile, Elena Arranz Canales, Elena Martín-Hernández, María Juliana Ballesta-Martínez, Encarna Guillén-Navarro, Guillem Pintos-Morell, Marc Moltó-Abad, David Moreno-Martínez, Salvador García Morillo, Javier Blasco-Alonso, María Luz Couce, Ricardo Gil Sánchez, Elisenda Cortès-Saladelafont, Mónica A. López Rodríguez, María Teresa García-Silva, and Montserrat Morales Conejo. Clinical features and health-related quality of life in adult patients with mucopolysaccharidosis iva: the spanish experience. Orphanet Journal of Rare Diseases, Nov 2021. URL: https://doi.org/10.1186/s13023-021-02074-y, doi:10.1186/s13023-021-02074-y. This article has 16 citations and is from a peer-reviewed journal.

  6. (alsayed2024consensusbasedexpertrecommendations pages 5-6): Moeenaldeen AlSayed, Dia Arafa, Huda Al-Khawajha, Manal Afqi, Nouriya Al-Sanna’a, Rawda Sunbul, and Maha Faden. Consensus-based expert recommendations on the management of mps iva and vi in saudi arabia. Orphanet Journal of Rare Diseases, Jul 2024. URL: https://doi.org/10.1186/s13023-024-03237-3, doi:10.1186/s13023-024-03237-3. This article has 3 citations and is from a peer-reviewed journal.

  7. (sawamoto2020mucopolysaccharidosisivadiagnosis pages 20-22): Kazuki Sawamoto, José Álvarez González, Matthew Piechnik, Francisco Otero, Maria Couce, Yasuyuki Suzuki, and Shunji Tomatsu. Mucopolysaccharidosis iva: diagnosis, treatment, and management. International Journal of Molecular Sciences, 21:1517, Feb 2020. URL: https://doi.org/10.3390/ijms21041517, doi:10.3390/ijms21041517. This article has 160 citations.

  8. (cleary2021impactoflongterm pages 1-2): Maureen Cleary, James Davison, Rachel Gould, Tarekegn Geberhiwot, Derralynn Hughes, Jean Mercer, Alexandra Morrison, Elaine Murphy, Saikat Santra, James Jarrett, Swati Mukherjee, and Karolina M. Stepien. Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type iva: results from a managed access agreement in england. Orphanet Journal of Rare Diseases, Jan 2021. URL: https://doi.org/10.1186/s13023-021-01675-x, doi:10.1186/s13023-021-01675-x. This article has 27 citations and is from a peer-reviewed journal.

  9. (NCT00884949 chunk 1): A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA. BioMarin Pharmaceutical. 2009. ClinicalTrials.gov Identifier: NCT00884949

  10. (magner2022consensusstatementon pages 1-2): Martin Magner, Zsuzsanna Almássy, Zoran Gucev, Beata Kieć-Wilk, Vasilica Plaiasu, Anna Tylki-Szymańska, Dimitrios Zafeiriou, Ioannis Zaganas, and Christina Lampe. Consensus statement on enzyme replacement therapy for mucopolysaccharidosis iva in central and south-eastern european countries. Orphanet Journal of Rare Diseases, May 2022. URL: https://doi.org/10.1186/s13023-022-02332-7, doi:10.1186/s13023-022-02332-7. This article has 11 citations and is from a peer-reviewed journal.

  11. (alsayed2024consensusbasedexpertrecommendations pages 6-8): Moeenaldeen AlSayed, Dia Arafa, Huda Al-Khawajha, Manal Afqi, Nouriya Al-Sanna’a, Rawda Sunbul, and Maha Faden. Consensus-based expert recommendations on the management of mps iva and vi in saudi arabia. Orphanet Journal of Rare Diseases, Jul 2024. URL: https://doi.org/10.1186/s13023-024-03237-3, doi:10.1186/s13023-024-03237-3. This article has 3 citations and is from a peer-reviewed journal.

  12. (kenth2024novelapproachfor pages 9-12): Johnny Kenth, Elizabeth Maughan, Colin R Butler, Jasleen Gabrie, Maral Rouhani, Benjamin Silver, Olumide K Ogunbiyi, Stuart Wilkinson, Reema Nandi, Robert Walker, Nagarajan Muthialu, Simon Jones, Richard Hewitt, and Iain A Bruce. Novel approach for tracheal resection in morquio a syndrome with end-stage critical airway obstruction: a uk case series. Orphanet Journal of Rare Diseases, Jul 2024. URL: https://doi.org/10.1186/s13023-024-03253-3, doi:10.1186/s13023-024-03253-3. This article has 3 citations and is from a peer-reviewed journal.

  13. (kenth2024novelapproachfor pages 1-2): Johnny Kenth, Elizabeth Maughan, Colin R Butler, Jasleen Gabrie, Maral Rouhani, Benjamin Silver, Olumide K Ogunbiyi, Stuart Wilkinson, Reema Nandi, Robert Walker, Nagarajan Muthialu, Simon Jones, Richard Hewitt, and Iain A Bruce. Novel approach for tracheal resection in morquio a syndrome with end-stage critical airway obstruction: a uk case series. Orphanet Journal of Rare Diseases, Jul 2024. URL: https://doi.org/10.1186/s13023-024-03253-3, doi:10.1186/s13023-024-03253-3. This article has 3 citations and is from a peer-reviewed journal.

  14. (kenth2024novelapproachfor pages 12-13): Johnny Kenth, Elizabeth Maughan, Colin R Butler, Jasleen Gabrie, Maral Rouhani, Benjamin Silver, Olumide K Ogunbiyi, Stuart Wilkinson, Reema Nandi, Robert Walker, Nagarajan Muthialu, Simon Jones, Richard Hewitt, and Iain A Bruce. Novel approach for tracheal resection in morquio a syndrome with end-stage critical airway obstruction: a uk case series. Orphanet Journal of Rare Diseases, Jul 2024. URL: https://doi.org/10.1186/s13023-024-03253-3, doi:10.1186/s13023-024-03253-3. This article has 3 citations and is from a peer-reviewed journal.

  15. (rintz2024adenoassociatedvirusbasedgene pages 1-2): Estera Rintz, Betul Celik, Nidhi Fnu, Angélica María Herreño-Pachón, Shaukat Khan, Eliana Benincore-Flórez, and Shunji Tomatsu. Adeno-associated virus-based gene therapy delivering combinations of two growth-associated genes to mps iva mice. Molecular Therapy - Nucleic Acids, 35:102211, Jun 2024. URL: https://doi.org/10.1016/j.omtn.2024.102211, doi:10.1016/j.omtn.2024.102211. This article has 2 citations.

  16. (crippa2024aglb1transgene pages 14-16): Stefania Crippa, Gaia Alberti, Laura Passerini, Evelyn Oliva Savoia, Marilena Mancino, Giada De Ponti, Ludovica Santi, Margherita Berti, Marialuisa Testa, Raisa Jofra Hernandez, Pamela Quaranta, Selene Ceriotti, Ilaria Visigalli, Amelia Morrone, Antonella Paoli, Claudia Forni, Serena Scala, Massimo Degano, Leopoldo Staiano, Silvia Gregori, Alessandro Aiuti, and Maria Ester Bernardo. A glb1 transgene with enhanced therapeutic potential for the preclinical development of ex-vivo gene therapy to treat mucopolysaccharidosis type ivb. Molecular Therapy - Methods & Clinical Development, 32:101313, Sep 2024. URL: https://doi.org/10.1016/j.omtm.2024.101313, doi:10.1016/j.omtm.2024.101313. This article has 4 citations.

  17. (kenth2024novelapproachfor pages 4-6): Johnny Kenth, Elizabeth Maughan, Colin R Butler, Jasleen Gabrie, Maral Rouhani, Benjamin Silver, Olumide K Ogunbiyi, Stuart Wilkinson, Reema Nandi, Robert Walker, Nagarajan Muthialu, Simon Jones, Richard Hewitt, and Iain A Bruce. Novel approach for tracheal resection in morquio a syndrome with end-stage critical airway obstruction: a uk case series. Orphanet Journal of Rare Diseases, Jul 2024. URL: https://doi.org/10.1186/s13023-024-03253-3, doi:10.1186/s13023-024-03253-3. This article has 3 citations and is from a peer-reviewed journal.

  18. (zabihi2024identificationofnew pages 1-2): Rezvan Zabihi, Mina Zamani, Majid Aminzadeh, Niloofar Chamanrou, Fatemeh Zahra Kiani, Tahere Seifi, Jawaher Zeighami, Tahere Yadegari, Alireza Sedaghat, Alihossein Saberi, Mohammad Hamid, Gholamreza Shariati, and Hamid Galehdari. Identification of new variants in patients with mucopolysaccharidosis in consanguineous iranian families. Frontiers in Genetics, Feb 2024. URL: https://doi.org/10.3389/fgene.2024.1343094, doi:10.3389/fgene.2024.1343094. This article has 2 citations and is from a peer-reviewed journal.

  19. (NCT01242111 chunk 2): A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome). BioMarin Pharmaceutical. 2010. ClinicalTrials.gov Identifier: NCT01242111

  20. (alsayed2024consensusbasedexpertrecommendations pages 2-4): Moeenaldeen AlSayed, Dia Arafa, Huda Al-Khawajha, Manal Afqi, Nouriya Al-Sanna’a, Rawda Sunbul, and Maha Faden. Consensus-based expert recommendations on the management of mps iva and vi in saudi arabia. Orphanet Journal of Rare Diseases, Jul 2024. URL: https://doi.org/10.1186/s13023-024-03237-3, doi:10.1186/s13023-024-03237-3. This article has 3 citations and is from a peer-reviewed journal.

  21. (ago2024molecularmechanismsin pages 1-2): Yasuhiko Ago, Estera Rintz, Krishna Sai Musini, Zhengyu Ma, and Shunji Tomatsu. Molecular mechanisms in pathophysiology of mucopolysaccharidosis and prospects for innovative therapy. International Journal of Molecular Sciences, 25:1113, Jan 2024. URL: https://doi.org/10.3390/ijms25021113, doi:10.3390/ijms25021113. This article has 33 citations.

  22. (ago2024molecularmechanismsin pages 7-9): Yasuhiko Ago, Estera Rintz, Krishna Sai Musini, Zhengyu Ma, and Shunji Tomatsu. Molecular mechanisms in pathophysiology of mucopolysaccharidosis and prospects for innovative therapy. International Journal of Molecular Sciences, 25:1113, Jan 2024. URL: https://doi.org/10.3390/ijms25021113, doi:10.3390/ijms25021113. This article has 33 citations.

  23. (ago2024molecularmechanismsin pages 11-14): Yasuhiko Ago, Estera Rintz, Krishna Sai Musini, Zhengyu Ma, and Shunji Tomatsu. Molecular mechanisms in pathophysiology of mucopolysaccharidosis and prospects for innovative therapy. International Journal of Molecular Sciences, 25:1113, Jan 2024. URL: https://doi.org/10.3390/ijms25021113, doi:10.3390/ijms25021113. This article has 33 citations.

  24. (ago2024molecularmechanismsin pages 2-3): Yasuhiko Ago, Estera Rintz, Krishna Sai Musini, Zhengyu Ma, and Shunji Tomatsu. Molecular mechanisms in pathophysiology of mucopolysaccharidosis and prospects for innovative therapy. International Journal of Molecular Sciences, 25:1113, Jan 2024. URL: https://doi.org/10.3390/ijms25021113, doi:10.3390/ijms25021113. This article has 33 citations.

  25. (akyol2019recommendationsforthe pages 1-2): Mehmet Umut Akyol, Tord D. Alden, Hernan Amartino, Jane Ashworth, Kumar Belani, Kenneth I. Berger, Andrea Borgo, Elizabeth Braunlin, Yoshikatsu Eto, Jeffrey I. Gold, Andrea Jester, Simon A. Jones, Cengiz Karsli, William Mackenzie, Diane Ruschel Marinho, Andrew McFadyen, Jim McGill, John J. Mitchell, Joseph Muenzer, Torayuki Okuyama, Paul J. Orchard, Bob Stevens, Sophie Thomas, Robert Walker, Robert Wynn, Roberto Giugliani, Paul Harmatz, Christian Hendriksz, and Maurizio Scarpa. Recommendations for the management of mps iva: systematic evidence- and consensus-based guidance. Orphanet Journal of Rare Diseases, Jun 2019. URL: https://doi.org/10.1186/s13023-019-1074-9, doi:10.1186/s13023-019-1074-9. This article has 162 citations and is from a peer-reviewed journal.

  26. (kenth2024novelapproachfor pages 8-9): Johnny Kenth, Elizabeth Maughan, Colin R Butler, Jasleen Gabrie, Maral Rouhani, Benjamin Silver, Olumide K Ogunbiyi, Stuart Wilkinson, Reema Nandi, Robert Walker, Nagarajan Muthialu, Simon Jones, Richard Hewitt, and Iain A Bruce. Novel approach for tracheal resection in morquio a syndrome with end-stage critical airway obstruction: a uk case series. Orphanet Journal of Rare Diseases, Jul 2024. URL: https://doi.org/10.1186/s13023-024-03253-3, doi:10.1186/s13023-024-03253-3. This article has 3 citations and is from a peer-reviewed journal.

  27. (kenth2024novelapproachfor media 9eafb273): Johnny Kenth, Elizabeth Maughan, Colin R Butler, Jasleen Gabrie, Maral Rouhani, Benjamin Silver, Olumide K Ogunbiyi, Stuart Wilkinson, Reema Nandi, Robert Walker, Nagarajan Muthialu, Simon Jones, Richard Hewitt, and Iain A Bruce. Novel approach for tracheal resection in morquio a syndrome with end-stage critical airway obstruction: a uk case series. Orphanet Journal of Rare Diseases, Jul 2024. URL: https://doi.org/10.1186/s13023-024-03253-3, doi:10.1186/s13023-024-03253-3. This article has 3 citations and is from a peer-reviewed journal.

  28. (sawamoto2020mucopolysaccharidosisivadiagnosis pages 11-13): Kazuki Sawamoto, José Álvarez González, Matthew Piechnik, Francisco Otero, Maria Couce, Yasuyuki Suzuki, and Shunji Tomatsu. Mucopolysaccharidosis iva: diagnosis, treatment, and management. International Journal of Molecular Sciences, 21:1517, Feb 2020. URL: https://doi.org/10.3390/ijms21041517, doi:10.3390/ijms21041517. This article has 160 citations.